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Developmental Role Of H19 And Igf2 In Mouse And Human
Abstract
Genomic imprinting is a mammalian-specific phenomenon where gene expression is regulated differently
between maternally- or paternally-inherited alleles. As most imprinted genes are important growth
regulators, proper expression of these genes is crucial for normal development in humans and mice. A
well-known H19/IGF2 imprinted cluster harbors two growth regulators with opposite functions, H19 and
IGF2. The maternally expressed H19 gene is a long noncoding RNA implicated in growth suppression,
while the paternally expressed IGF2 gene is a major growth factor in multiple developmental pathways.
Dysregulation of the imprinted H19/IGF2 cluster is associated with Beckwith-Wiedemann Syndrome
(BWS) and Silver-Russel Syndrome (SRS). Although both are primarily represented by abnormal growth,
BWS and SRS show substantial variability in the severity of symptoms among patients. The mechanism
underlying how the dysregulated H19/IGF2 expression leads to a specific pathological defect is still
unknown. BWS and SRS phenotypes have been largely attributed to aberrant IGF2 expression because the
exact role of H19 has been difficult to discern due to its coupled regulation with IGF2. Additionally,
because of the mosaic nature of the epimutations in human patients, it has been challenging to
understand the contribution of abnormally expressed H19 and IGF2 to the tissue-specific BWS/SRS
pathologies. To dissect the effect of H19/IGF2 dysregulation in various lineages, we utilized two model
systems. In chapter 2, we present the human induced pluripotent stem cells (hiPSCs) that are derived
from BWS patient fibroblasts with paternal uniparental disomy of chromosome 11 (pUPD11). Our iPSC
clones maintained proper imprinting in H19/IGF2 locus with an expected epigenetic profile of pUPD11.
Differentiation of hiPSCs into a hepatic lineage enabled us to examine the effect of pUPD11 in a tissue
type that is prone to BWS-related tumors. Through the transcriptomic profiling of pUPD11 and nonpUPD11 hepatocytes, we could identify the target pathways that are affected by pUPD11 and likely
contributing to the increased occurrence of hepatoblastoma and growth anomalies in BWS. In chapter 3,
we utilized mouse models with subtle perturbations of H19 and Igf2 expression to address the
independent roles of H19 and Igf2 in SRS-like pathologies. We started with a previously described
humanized mouse model that substituted the human H19 imprinting control region for the corresponding
mouse region (H19+/hIC1), which exhibited H19 overexpression and Igf2 depletion. These mice had
severe developmental defects in the heart and placenta, which may significantly contribute to the
previously described perinatal lethality and severe growth restriction. While normalizing H19 expression
was not sufficient for the full rescue of the growth restriction and lethality, altering both H19 and Igf2
expression restored viability, although certain cardiac defects were still retained. Our results demonstrate
that physiological levels of H19 and Igf2 are crucial for normal cardiac and placental development.
Overall, this work emphasizes the importance of precise regulation of H19 and IGF2 expression in
embryonic growth and tissue formation. These results enhance our understanding of how molecular
defects in the H19/IGF2 cluster lead to the characteristic BWS and SRS phenotypes, further helping to
establish molecular subtype-specific therapeutic strategies.
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ABSTRACT
DEVELOPMENTAL ROLE OF H19 AND IGF2 IN MOUSE AND HUMAN
Suhee Chang
Marisa S. Bartolomei
Genomic imprinting is a mammalian-specific phenomenon where gene expression is
regulated differently between maternally- or paternally-inherited alleles. As most imprinted genes
are important growth regulators, proper expression of these genes is crucial for normal
development in humans and mice. A well-known H19/IGF2 imprinted cluster harbors two growth
regulators with opposite functions, H19 and IGF2. The maternally expressed H19 gene is a long
noncoding RNA implicated in growth suppression, while the paternally expressed IGF2 gene is a
major growth factor in multiple developmental pathways. Dysregulation of the imprinted
H19/IGF2 cluster is associated with Beckwith-Wiedemann Syndrome (BWS) and Silver-Russel
Syndrome (SRS). Although both are primarily represented by abnormal growth, BWS and SRS
show substantial variability in the severity of symptoms among patients. The mechanism
underlying how the dysregulated H19/IGF2 expression leads to a specific pathological defect is
still unknown. BWS and SRS phenotypes have been largely attributed to aberrant IGF2
expression because the exact role of H19 has been difficult to discern due to its coupled
regulation with IGF2. Additionally, because of the mosaic nature of the epimutations in human
patients, it has been challenging to understand the contribution of abnormally expressed H19 and
IGF2 to the tissue-specific BWS/SRS pathologies. To dissect the effect of H19/IGF2
dysregulation in various lineages, we utilized two model systems. In chapter 2, we present the
human induced pluripotent stem cells (hiPSCs) that are derived from BWS patient fibroblasts
with paternal uniparental disomy of chromosome 11 (pUPD11). Our iPSC clones maintained
proper imprinting in H19/IGF2 locus with an expected epigenetic profile of pUPD11.
iv

Differentiation of hiPSCs into a hepatic lineage enabled us to examine the effect of pUPD11 in a
tissue type that is prone to BWS-related tumors. Through the transcriptomic profiling of pUPD11
and non-pUPD11 hepatocytes, we could identify the target pathways that are affected by pUPD11
and likely contributing to the increased occurrence of hepatoblastoma and growth anomalies in
BWS. In chapter 3, we utilized mouse models with subtle perturbations of H19 and Igf2
expression to address the independent roles of H19 and Igf2 in SRS-like pathologies. We started
with a previously described humanized mouse model that substituted the human H19 imprinting
control region for the corresponding mouse region (H19+/hIC1), which exhibited H19
overexpression and Igf2 depletion. These mice had severe developmental defects in the heart and
placenta, which may significantly contribute to the previously described perinatal lethality and
severe growth restriction. While normalizing H19 expression was not sufficient for the full rescue
of the growth restriction and lethality, altering both H19 and Igf2 expression restored viability,
although certain cardiac defects were still retained. Our results demonstrate that physiological
levels of H19 and Igf2 are crucial for normal cardiac and placental development. Overall, this
work emphasizes the importance of precise regulation of H19 and IGF2 expression in embryonic
growth and tissue formation. These results enhance our understanding of how molecular defects
in the H19/IGF2 cluster lead to the characteristic BWS and SRS phenotypes, further helping to
establish molecular subtype-specific therapeutic strategies.
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CHAPTER 1. INTRODUCTION
1.1 Genomic imprinting and related genetic disorders
A small number of mammalian genes are expressed in a parent-of-origin specific manner
via an epigenetic phenomenon known as genomic imprinting (Barlow and Bartolomei, 2014).
Imprinted genes are typically found clustered in the genome and have important developmental
roles, including the control of fetal growth and placental function (Plasschaert and Bartolomei,
2014). Genomic imprinting is largely regulated by the differential DNA methylation of discrete
genomic elements located within imprinted clusters, which are called imprinting control regions
(ICRs) (Li, Beard and Jaenisch, 1993; Edwards and Ferguson-Smith, 2007). ICRs are methylated
on a single parental allele during gametogenesis. Normally, this methylation state is maintained
throughout development despite the genome-wide epigenetic reprogramming that occurs after
fertilization in the early embryo (Barlow and Bartolomei, 2014). Offspring with improper DNA
methylation, inherited or somatic mutations and partial deletions of ICRs may exhibit abnormal
genomic imprinting. Perturbations of imprinted genes and their regulation often lead to abnormal
pre- and post-natal growth, as exemplified by the human imprinting disorders BeckwithWiedemann syndrome (BWS), Silver-Russell syndrome (SRS), Prader-Willi syndrome (PWS)
and Angelman syndrome (AS).

1.1.1. H19/IGF2 imprinted cluster
The H19/IGF2 locus includes two imprinted genes located at 11p15.5 in human and at
distal chromosome 7 in mouse (Figure 1.1). In humans, telomeric to the ICR (designated as IC1)
resides H19, which encodes a cytoplasmic long noncoding RNA (lncRNA). H19 is associated
with growth suppression, delayed placental growth, cell cycle regulation, cardiac remodeling,
1

tumorigenesis and metastasis (Yoshimizu et al., 2008; Lecerf, Le Bourhis and Adriaenssens,
2019; Zhou et al., 2019). H19 lncRNA may be processed into a microRNA (MIR675/Mir675),
although its exact role remains unclear (Mineno et al., 2006; Keniry et al., 2012). Centromeric to
IC1 resides IGF2, which encodes a fetal growth-promoting protein essential for proper organ
development and an intronic microRNA (MIR483/miR483) (Figure1.1). In various tissues, IGF2
promotes cell proliferation and differentiation (Dandolo et al., 2013; Ferrón et al., 2015).

Regulation of H19/Igf2 imprinting
In both mouse and human, H19 and Igf2 are regulated by the ICR and share tissuespecific enhancers located downstream of H19 (Figure 1.1A and B) (Leighton et al., 1995;
Kaffer, Grinberg and Pfeifer, 2001). The maternal ICR is unmethylated and bound by the
architectural protein CTCF (Bell, West and Felsenfeld, 1999; Bell and Felsenfeld, 2000; Lee and
Bartolomei, 2013). CTCF maintains the unmethylated state of the maternal ICR and functions as
an insulator to prevent the downstream enhancers from interacting with the maternal Igf2
promoter (Yoon et al., 2007). Consequently, Igf2 is silenced and H19 is expressed on the
maternal allele. Conversely, the paternal H19/Igf2 ICR is methylated during spermatogenesis.
Following fertilization, this methylation spreads to the paternal H19 promoter and silences the
paternal H19 (Thorvaldsen, Duran and Bartolomei, 1998). Additionally, the methylation of the
paternal ICR interferes with CTCF binding and formation of the insulator. As a result, Igf2 is
expressed and H19 is silenced on the paternal allele. The ICR is critical in allele-specific
regulation of Igf2 and H19, as shown in a mouse model with the ICR deletion (Figure 1.1C,
Δ3.8kb-5’H19 (Thorvaldsen et al., 2002, 2006) and K519 (Kaffer et al., 2000)). When the
H19/Igf2 ICR was deleted on the maternal allele, the normally silent maternal Igf2 was activated,
increasing the fetal weight.

2

1.1.2. CDKN1C/KCNQ1OT1 cluster
Centromeric to the human H19/IGF2 cluster (Figure 1.2A) and telomeric to the mouse
cluster (Figure 1.2B) is the CDKN1C/KCNQ1OT1 cluster. The ICR of this cluster (designated as
IC2 in humans and as KvDMR1 in mice) and its regulatory mechanisms are conserved. KvDMR1
regulates allelic expression of multiple imprinted genes in the cluster, including Kcnq1ot1,
Cyclin-dependent kinase inhibitor (Cdkn1c or p57Kip2), Slc22a18, Phlda2, Ascl2 and Kcnq1. Each
of these imprinted genes plays important roles in development. For example, (1) Cdkn1c
regulates cell proliferation and promotes cell cycle arrest (Hatada and Mukai, 1995; Matsuoka et
al., 1996); (2) Kcnq1 encodes a potassium channel and is imprinted at specific developmental
stages and tissues (Wang et al., 1996; Lee et al., 1997); (3) Ascl2 encodes a placenta-specific
transcription factor (Guillemot et al., 1995; McLaughlin et al., 1996); and (4) Phlda2 regulates
placental growth and hormone synthesis (Jensen, Tunster and John, 2014).

Regulation of Cdkn1c/Kcnq1ot1 imprinting
The Cdkn1c/Kcnq1ot1 locus is primarily regulated by the lncRNA Kcnq1ot1. The
Kcnq1ot1 promoter resides within KvDMR1, which is methylated on the maternal allele and
unmethylated on the paternal allele. Kcnq1ot1 transcription is essential for proper imprinting of
the Cdkn1c/Kcnq1ot1 locus. The unmethylated paternal KvDMR1 promotes the transcription of
Kcnq1ot1 to silence the linked imprinted genes, likely via the recruitment of repressive epigenetic
modulators including histone modifiers and DNA methyltransferases (Pandey et al., 2008;
Mohammad et al., 2010). Contrarily, the maternal KvDMR1 methylation silences Kcnq1ot1,
enabling the expression of the linked imprinted genes. This mechanism is supported by numerous
studies in mouse. For example, deleting KvDMR1 on the paternal allele disrupted allele-specific
regulation of Cdkn1c and other linked genes (Figure 1.2C, 2.8kb-KvDMR1Δ (Fitzpatrick,
Soloway and Higgins, 2002) and 3.6kb- DMRΔ (Mancini-DiNardo et al., 2006)). Deletion of the
3

paternal Kcnq1ot1 promoter in mice led to abnormal methylation and expression of genes in the
cluster (Figure 1.2C, PromΔ (Mancini-DiNardo et al., 2006) and Kcnq1ot1PO (Schultz et al.,
2015)). Indeed, the transcriptional activity of the Kcnq1ot1 promoter ensures the KvDMR1
hypomethylation and repression of Cdkn1c. Interestingly, others have shown that Kcnq1ot1 may
control the locus in most but not all tissues. Truncation of the paternal Kcnq1ot1 transcript derepressed paternal Cdkn1c expression in brain, heart, gut and placenta, but not in liver, kidney
and lung (Figure 1.2C, pA/YJ69 (Shin, Fitzpatrick and Higgins, 2008)). Thus, whereas the full
Kcnq1ot1 transcript is required to silence Cdkn1c and other genes in the cluster in most tissues,
an alternate mechanism, independent of Kcnq1ot1, may mediate Cdkn1c silencing in some
tissues.

1.1.3. Rationale for utilizing mouse models to study imprinted clusters
Since the discovery of genomic imprinting (McGrath and Solter, 1984; Surani, Barton
and Norris, 1984), mouse models have been a powerful tool to study genetic disorders associated
with abnormal imprints. The main advantage of the mouse lies in the largely conserved
mechanisms that govern genomic imprinting (Edwards and Ferguson-Smith, 2007; Lee and
Bartolomei, 2013). For each imprinted cluster, the genes, ICRs and epigenetic modifications
responsible for parent-of-origin specific expression are largely conserved between mice and
humans. Additionally, the prevalence of single nucleotide polymorphisms (SNPs) in numerous
mouse strains allows for elegant mating strategies and tracking of the maternal and paternal
alleles in offspring. Furthermore, the marks that designate the parental identity of imprinted genes
are established in the germline and can readily be evaluated in murine gametes. Importantly, loss
of imprinting often occurs early in development in cells and tissues that are not easily accessible
in humans but are accessible in the mouse. Nearly forty years after its discovery, mouse models
4

continue to serve as a vital tool to understand the physiological consequences of genomic
imprinting.

1.2. Beckwith-Wiedemann syndrome
Beckwith-Wiedemann syndrome (BWS, OMIM catalog #130650) is one of the most
common fetal overgrowth syndromes with an incidence of 1 in 10,000 to 13,700 births (Vora and
Bianchi, 2009; Mussa et al., 2013). Clinical features include pre- and postnatal overgrowth,
hemihypertrophy, macroglossia, neonatal hypoglycemia, hyperinsulinism and hypoglycemia,
organomegaly, renal abnormalities, anterior abdominal wall defects, umbilical hernia, ear creases,
increased susceptibility to congenital/childhood tumors such as Wilms tumor (WT),
adrenocortical carcinoma, hepatoblastoma and neuroblastoma, placentomegaly and placental
mesenchymal dysplasia (DeBaun, King and White, 2000; Bliek, 2001; Weksberg, Shuman and
Beckwith, 2010; Brioude et al., 2018a,b). Notably, these symptoms can vary substantially among
individuals. Although the molecular etiology of BWS is multifold, the vast majority of cases
involve genetic and epigenetic perturbations of two clusters of imprinted genes on 11p15: the
H19/IGF2 cluster and CDKN1C/KCNQ1OT1 cluster.

1.2.1. Genetic and Epigenetic Errors of BWS
Most BWS patients have genetic or epigenetic errors at the H19/IGF2 cluster and/or the
CDKN1C/KCNQ1OT1 cluster, such as DNA methylation perturbations, copy number variants
and loss-of-function mutations of imprinted genes (Table 1.1). Indeed, the various epigenotypes
of BWS patients correlate with different phenotypes. For example, hemihypertrophy and
hypoglycemia are associated with paternal uniparental disomy (pUPD) of 11p15 (DeBaun et al.,
2002). Individuals with abnormal IC1 methylation are reported to have increased tumor risk
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(Bliek, 2001). H19/IGF2 imprinting is consistently dysregulated in BWS patients presenting with
Wilms’ tumors (Dao et al., 1999; Frevel et al., 1999). Gain-of-methylation (GoM) on IC1 is
strongly correlated with neonatal macrosomia and disproportionate overgrowth (Mussa et al.,
2016). Premature birth is associated with loss-of-methylation (LoM) on IC2 or CDKN1C
mutations (Mussa et al., 2016). Finally, patients with abdominal wall defects exhibit a higher
frequency of abnormal methylation on the CDKN1C/KCNQ1OT1 cluster (DeBaun et al., 2002).
Thus, elucidating the epigenetic mechanisms for the BWS imprinted clusters would inform our
understanding of how certain mutations cause defined pathological phenotypes, ultimately
leading to better treatment plans for patients. Given the conserved biology and regulation of
IC1/IC2, the investigation of dysregulated human imprinting using mouse models has been
particularly informative.

1.2.2. H19/IGF2 cluster in BWS
Dysregulated H19/IGF2 expression leading to BWS phenotypes
Given that H19 and IGF2 are key regulators in development, it is expected that
perturbations in gene dose promote abnormal growth. For example, overexpression of Igf2 caused
by introducing Igf2 transgene in mice causes fetal overgrowth similar to the human BWS
phenotype (Sun et al., 1997). A mouse carrying an H19 deletion on the maternal allele exhibited
fetal overgrowth and tissue-specific activation of maternal Igf2 (Fig 1C, H19Δ3 (Ripoche et al.,
1997) and loxΔH19 (Schmidt, Levorse and Tilghman, 1999)). Additionally, H19 and IGF2 can
work together to control growth. Early work suggested that H19 is a trans-acting repressor of Igf2
(Li et al., 1998). Transgenic overexpression of H19 in H19Δ3 mice rescued overgrowth and
restored H19 and Igf2 expression to wild-type levels (Gabory et al., 2009; Martinet et al., 2016),
suggesting that H19 may function as a repressor of Igf2. In conclusion, absence of H19 and/or
increased Igf2 can lead to overgrowth in early development.
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GoM on IC1
5-10% of BWS patients exhibit GoM or IC1 hypermethylation at the H19/IGF2 locus
(Table 1.1). DNA methylation antagonizes CTCF binding (Kanduri et al., 2000; Wang et al.,
2012). Therefore, hypermethylation of IC1 on the normally unmethylated maternal allele can
prevent CTCF binding, which disfavors H19 expression and increases IGF2 expression. CTCF is
indispensable for both insulating Igf2 and maintaining the unmethylated state of maternal IC1. In
mice, targeted deletion of all 4 CTCF binding sites (CTSs) within the maternal H19/Igf2 ICR
resulted in hypermethylation of mutant maternal ICR, loss of CTCF-mediated insulator function
and therefore biallelic Igf2 expression (Figure 1.1C, DMD-ΔR (Engel, Thorvaldsen and
Bartolomei, 2006a)). Similar results were obtained when the 4 CTSs were mutated on the
maternal H19/Igf2 ICR, where the mice exhibited variable acquisition of DNA methylation and
maternal Igf2 activation (Figure 1.1C, CTS mutation (Schoenherr, Levorse and Tilghman, 2003;
Szabo et al., 2004)). These models underscore the importance of proper CTCF binding to the ICR
for allele-specific regulation of H19/Igf2 expression.

The causes of IC1 hypermethylation remain unclear. The relationship between IC1
mutations, IC1 hypermethylation and BWS phenotypes is complex (Table 1.1) (Brioude et al.,
2018a,b; Duffy et al., 2019b). IC1 hypermethylation is often associated with microdeletions
(Sparago et al., 2004), which may change the spacing of CTSs and affect CTCF binding,
insulator activity and DNA methylation of IC1. Therefore, it is possible that the variable BWS
phenotypes may stem from the spatial arrangement of CTCF binding sites specific to each
microdeletion (Beygo et al., 2013). For example, in one representative BWS family, transmission
of a specific IC1 mutation over generations was accompanied by a gradual increase in DNA
methylation (Berland et al., 2013). On the other hand, another BWS family with an IC1
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microdeletion had no IC1 methylation abnormalities (Prawitt et al., 2005). In this study, a family
member carrying a maternally inherited IC1 microdeletion and a duplication of chr11p15
presented with BWS symptoms, whereas other relatives with the same maternal IC1 deletion did
not. Additional studies document incomplete penetrance of BWS features despite all relatives
carrying the same IC1 microdeletion (Cerrato et al., 2008; Berland et al., 2013). One factor that
may contribute to this clinical heterogeneity is the developmental stage at which the IC1 deletion
occurs. For example, one BWS study identified a point mutation within IC1 that originated from
the paternal allele of a patient’s grandmother (Berland et al., 2013). During oogenesis in this
grandmother, IC1 reprogramming (i.e. removal of paternally methylated epigenetic marks and
establishment of maternally unmethylated marks) could have been disrupted by the mutation,
resulting in incomplete demethylation of the mutant IC1. Once this hypermethylated IC1 was
maternally inherited, methylation gradually accumulated on the mutant IC1 over generations.
Consistently, mouse studies showed imprinted H19 expression was not affected when the paternal
H19/Igf2 ICR was deleted after methylation of the H19 promoter was established (Figure 1.1C,
DMRΔ (Srivastava et al., 2000)).

It is important to note that genetic lesions at IC1 are not always accompanied by
hypermethylation, and the aberrant methylation patterns are not necessarily caused by IC1
mutations. For example, a subset of BWS patients exhibited IC1 hypermethylation but did not
carry any identified genetic lesions (Cerrato et al., 2008). Another factor that can explain the
heterogeneity in BWS is epigenetic mosaicism (Abi Habib et al., 2017). IC1 hypermethylation is
often mosaic in BWS patients and is independent of the mutations (Cerrato et al., 2008). Mosaic
expression was also observed at a single cell level in mice harboring ICR mutations (Ginart et al.,
2016). The fact that hypermethylation exhibits a mosaic pattern suggests that the
hypermethylation is acquired after fertilization, instead of in the germline.
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Two important questions remain regarding hypermethylation and IC1 microdeletions
associated with BWS: (1) are both maternally-derived genetic lesions and hypermethylation
causing BWS or (2) is GoM the consequence of the microdeletion? To understand the
relationship between microdeletions and IC1 hypermethylation, researchers have utilized mouse
models with partial deletions in H19/Igf2 ICR. Although the regulatory mechanisms of the locus
are well conserved, the mouse H19/Igf2 ICR differs from the human IC1 in the number of CTSs,
genomic size, and nucleotide sequence (Figure 1.1A and B). Consequently, the optimal way to
understand BWS lesions using a mouse model is through ICR deletions that remove CTCF
binding sites. Deletion of two of four CTSs on the maternal H19/Igf2 ICR resulted in tissuespecific activation of maternal Igf2 and increased birth weight, despite the normal methylation of
the mutant ICR (Figure 1.1C, Δ2,3 (Ideraabdullah et al., 2014)). This model demonstrates that
partial deletion of the H19/Igf2 ICR is not always accompanied by ICR hypermethylation and that
ICR hypermethylation is not strictly required for abnormal H19/Igf2 expression and growth. In
contrast, when a larger ICR deletion containing three CTSs was maternally transmitted, the
mutant maternal ICR gained methylation and maternal Igf2 was activated (Figure 1.1C, ΔDMD
(Thorvaldsen, Duran and Bartolomei, 1998; Thorvaldsen et al., 2002, 2006)). Similarly, when all
four CTSs were deleted or mutated in the maternal H19/Igf2 ICR, the mutant ICR acquired
methylation and H19/Igf2 imprinting was disrupted ubiquitously (Figure 1.1C, CTS mutation
(Schoenherr, Levorse and Tilghman, 2003; Szabo et al., 2004; Engel, Thorvaldsen and
Bartolomei, 2006a)). These models suggest that the nature of the ICR deletions determines
whether there will be accompanying hypermethylation, although it is unclear whether the deletion
size, position or sequence are critical to determine whether the ICR is protected from ectopic
hypermethylation. Therefore, a subset of IC1 microdeletions that disrupt key aspects of IC1 may
result in its hypermethylation and ultimately BWS.
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As stated above, due to a lack of ICR sequence conservation, mice are limited in
modeling the exact BWS mutations observed in humans. To recapitulate human mutations more
precisely, Hur and colleagues generated a mouse strain with human IC1 (hIC1) substituted for the
endogenous murine H19/Igf2 ICR (Figure 1.1A, hIC1 (Hur et al., 2016)). The paternally
transmitted hIC1 allele failed to acquire and maintain the normal hypermethylation (see further
discussion below). However, when maternally inherited, the hIC1 allele exhibited normal
hypomethylation and CTCF insulator function, suggesting a possible system to model human
BWS mutations endogenously in mice. For example, Freschi et al. designed a mouse strain with
hIC1 including a 2.2-kb deletion found in BWS patients (Figure 1.1A, hIC1Δ2.2 (Freschi et al.,
2018)). Maternal transmission of this mutant hIC1 resulted in tissue-specific overexpression of
Igf2, successfully mimicking clinical BWS phenotypes including pre/post-natal overgrowth,
nephromegaly, macroglossia and kidney asymmetry. Notably, mutant hIC1 gained methylation
when maternally transmitted, possibly because the removal of three CTSs reduced CTCF binding
to the IC1. Thus, humanized mouse models offer a powerful tool to mimic the epigenetic and
genetic errors found in human BWS patients and examine their physiological consequences.

1.2.3. CDKN1C/KCNQ1OT1 cluster in BWS
50% of BWS patients exhibit LoM at IC2 (Table 1.1). In these cases, the lncRNA
KCNQ1OT1 is predicted to be ectopically expressed from the maternal allele, which silences the
growth suppressor CDKN1C and other maternally expressed genes. Importantly, loss of CDKN1C
expression is a major cause of the overgrowth phenotype in BWS patients. Knockout of maternal
Cdkn1c in mice causes similar fetal overgrowth, as well as cleft palate, abdominal wall defects
and placental defects such as placentomegaly that approximate the BWS phenotype (Yan et al.,
1997; Zhang et al., 1997; Tunster, Van De Pette and John, 2011).
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Dysregulation of other IC2-controlled genes in addition to CDKN1C can contribute to
BWS-like phenotypes. One such pathway involves PHLDA2, a maternally expressed gene within
the IC2 cluster (Figure 1.2). In mice, maternal inheritance of a Phlda2 deletion resulted in
placentomegaly (Frank et al., 2002; Salas et al., 2004), which suggests that the dysregulation of
Phlda2 expression caused by disrupted imprinting of the IC2 cluster can lead to adverse placental
phenotypes, one of the hallmark BWS symptoms.

LoM on IC2
In a subset of BWS patients, LoM on IC2 may result from maternally transmitted
mutations, particularly those that affect transcription. Notably, work in mice has shown that
establishment of maternal allele-specific methylation on KvDMR1 requires active transcription of
Kcnq1 through KvDMR1 during oocyte maturation (Figure 1.3A (Chotalia et al., 2009; Singh et
al., 2017)). Thus, a defect in transcription may result in the failure to establish proper methylation
on maternal KvDMR1 (Figure 1.3B). Human BWS cases support this model. Valente et al.
described a BWS patient with maternal inheritance of a mutation affecting KCNQ1 transcription
and complete LoM at IC2 (Valente et al., 2019). In a second BWS family, disruption of KCNQ1
transcription by translocation of KCNQ1 exons to a different chromosome was associated with
abnormal IC2 methylation (Beygo et al., 2019). In a third report, a maternally inherited
microdeletion in KCNQ1OT1 coincided with IC2 LoM, CDKN1C silencing and BWS features
(Niemitz et al., 2004). To genetically dissect the role of transcription in IC2 imprinting in more
detail, mouse models harboring a truncated maternal Kcnq1 transcript just prior to KvDMR1 have
been generated. These mice exhibited LoM on the maternal KvDMR1, biallelic expression of
Kcnq1ot1 and repression of normally maternally-expressed genes, including Cdkn1c (Figure 1.2C
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and Figure 1.3B, YJ11 (Singh et al., 2017)). Together, these human and mouse studies suggest
that a mutation disrupting Kcnq1 transcription leads to the loss of imprinting of the entire cluster.

Despite solid evidence for this maternally based transcription model for LoM, the origin
of IC2 hypomethylation for many BWS patients remains unclear. Given the typical mosaic
pattern of LoM in different tissues, it is likely that the methylation defect occurs after
fertilization. This is particularly relevant for patients conceived using Assisted Reproductive
Technologies (ART) and, more specifically, in vitro fertilization (IVF). IVF is associated with a
higher than expected frequency of BWS and SRS cases that involve DNA methylation defects
(Johnson et al., 2018). One possible explanation for this observation is that IVF involves
manipulations of gametes and embryos at a time of epigenetic reprogramming. The genome
undergoes an extensive DNA methylation reprogramming after fertilization but DNA methylation
at imprints must survive this reprogramming (Morgan et al., 2005). The environmental
perturbations inherent to ART, i.e. hormone treatments and ex vivo manipulations, may affect the
fidelity of DNA methylation at imprinted genes in the early embryo (Vrooman and Bartolomei,
2017). Consistent with this hypothesis, mouse models of IVF have shown that simply culturing
embryos ex vivo can result in significant changes in DNA methylation (Doherty et al., 2000;
Mann et al., 2004). Therefore, environmental insults during early pregnancy may cause BWS in
children without inherited genetic mutations.

CDKN1C mutations and loss of expression
5 to 10% of all BWS patients carry deficiency or loss-of-function mutations of the growth
suppressor CDKN1C (Table 1.1) (Choufani, Shuman and Weksberg, 2013; Mussa et al., 2016).
Early clinical work determined that maternal CDKN1C expression was absent in Wilms’ tumors
(Matsuoka et al., 1996), suggesting that maternally-inherited loss-of-function mutations in
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CDKN1C can cause some of the classic symptoms of BWS. This human mutation inspired the
generation of mouse models with Cdkn1c mutations to study its role in BWS (Yan et al., 1997;
Zhang et al., 1997; Tunster, Van De Pette and John, 2011). Yan et al. reported an increase in the
number of apoptotic cells in affected organs, underscoring the role of Cdkn1c as a cell cycle
regulator. Cdkn1c mutant embryos were oversized at midgestation (Tunster, Van De Pette and
John, 2011), and showed abnormalities in muscles covering abdominal wall, recapitulaing
abdominal wall defects seen in BWS patients (Zhang et al., 1997; Tunster, Van De Pette and
John, 2011). To note, the fetal overgrowth of Cdkn1c mutant mice was reversed rapidly in late
gestation. Tunster et al. have suggested that intrauterine competition in mice may have masked
the fetal overgrowth caused by the lack of Cdkn1c, and singleton pregnancy in human allows
presentation of the overgrowth phenotype in BWS offspring (Tunster, Van De Pette and John,
2011).

1.2.4. pUPD11, spanning through H19/IGF2 and CDKN1C/KCNQ1OT1 clusters, in BWS
20-25% of BWS patients have pUPD of chromosome 11p15.5, where both copies of
11p15.5 are inherited from the father (Figure 1.1D and Table 1.1). Modeling pUPD11 in mice has
been difficult because pUPD of the corresponding region in mice (distal chromosome 7) is lethal
at midgestation (McLaughlin et al., 1996; Rentsendorj et al., 2010; Singh et al., 2011). Mouse
embryos with pUPD7 were developmentally delayed at 10.5 dpc, lacked placental
spongiotrophoblasts and were resorbed before 13.5 dpc. Although these embryos lacked H19 and
exhibited increased Igf2 expression, deleting paternal Igf2 failed to rescue their survivability
(Rentsendorj et al., 2010). Similarly, when only paternal Cdkn1c/Kcnq1ot1 cluster is left
functional due to the truncation of maternal distal chromosome 7, lethality was observed by 10.5
dpc in mice (DelTel7, Oh et al., 2008). Modeling pUPD11 in mice has been challenging due to
this embryonic lethality.
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The difference in UPD lethality between human and mouse may arise from the typical
presentation of mosaic mixture of UPD and non-UPD cells in human patients, whereas the
pUPD7 mice are constitutively UPD. Nevertheless, and perhaps more importantly, midgestation
lethality in mouse may be caused by loss of expression of the maternally expressed, imprinted
gene Ascl2, which is not imprinted in humans (Figure 1.2A) (Westerman et al., 2001; Miyamoto
et al., 2002; Rentsendorj et al., 2010). Consistently, the embryonic lethality of the
aforementioned DelTel7 mouse model was partially rescued by restoring Ascl2 expression
(Tunster et al., 2018). Together, these factors complicate the modeling of human pUPD11. To
overcome such limitations, several other methods have been developed to study imprinting
disorders, including human induced pluripotent cells (hiPSCs). Derived from BWS patients’
fibroblasts, the strength of this system is the preserved pathological genetic environment. This
eliminates the need to manipulate the genome to achieve the desired mutations and therefore
avoids the possible off-target effects of gene editing. Another advantage of the system is that
hiPSCs can be differentiated into clinically relevant tissues that are difficult to study in human
BWS patients. Combining information gleaned from hiPSCs and traditional mouse models will
enhance our understanding of the genetic mechanisms underlying imprinting disorders such as
BWS and SRS.

1.3. Silver-Russell Syndrome
Silver-Russell Syndrome (SRS, OMIM #180860) is a fetal undergrowth genetic disorder
with an incidence range of 1/30,000 to 1/100,000 (Wakeling et al., 2017a). Representative SRS
symptoms include lower birth weight, growth restriction lasting to adulthood, skeletal/limb
asymmetry, cognitive impairment together with delayed language development, macrocephaly,
fifth-finger clinodactyly and characteristic triangular face (Wakeling et al., 2017a). SRS is a
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“sister” epigenetic disorder of BWS. The dysregulation of the same gene cluster can cause either
the overgrowth observed in BWS or undergrowth in SRS. Consistently, depending on the parental
origin, the same genetic defect in imprinted clusters can result in increased or decreased
expression of these imprinted growth regulators.

1.3.1. H19/IGF2 cluster in SRS
LoM on IC1
Loss of IC1 methylation, independent of a genetic mutation in cis, is found in 50% of
SRS patients (Table 1.1). Normally, methylation on paternal IC1 prevents CTCF binding and
silences paternal H19. In SRS, the hypomethylated paternal IC1 is proposed to enable formation
of an ectopic CTCF insulator as demonstrated in a SRS mouse model (Engel et al., 2004; Gicquel
et al., 2005). As a result, there is activation of paternal H19 and decreased IGF2 expression.
Altered H19 and/or IGF2 expression can lead to abnormal growth because H19 and IGF2 are
growth regulators. In mice, paternal-specific deletion of Igf2 resulted in total loss of Igf2
expression and pre- and postnatal growth restriction (DeChiara, Robertson and Efstratiadis, 1991;
Haley et al., 2012). Moreover, transgenic H19 overexpression caused embryonic growth
restriction (Gabory et al., 2009). Therefore, improper H19/Igf2 expression caused by IC1 LoM
can cause abnormal development in SRS.

The consequences of IC1 LoM found in humans are explored further in the
aforementioned humanized mouse model (Figure 1.1A, hIC1 (Hur et al., 2016)). In these mice,
the paternally transmitted hIC1 failed to establish proper methylation during spermatogenesis,
enabling CTCF to function as an insulator on the paternal allele. Therefore, the offspring of these
sires exhibit highly elevated H19 expression, undetectable Igf2 expression, severe growth
restriction and perinatal lethality. In a different mouse model, mutating CpGs within CTSs of the
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paternal H19/Igf2 ICR caused loss of methylation (Figure 1.1C, DMD-9CG (Engel et al., 2004)).
This mutant ICR was unable to maintain methylation after fertilization, thereby promoting CTCF
binding and ectopic insulator function on the paternal allele. These offspring also display
activated paternal H19 and reduced Igf2 expression, culminating in restricted embryonic growth.

What can cause the IC1 LoM in SRS patients? As with BWS methylation abnormalities,
SRS patients typically present with a mosaic pattern of methylation (Table 1.1) (Eggermann et
al., 2016). This mosaic pattern suggests that LoM may occur post-fertilization and may be linked
to an unfavorable embryonic/fetal environment. ART/IVF strategies represent an example of an
environmental insult on the methylome. Similar to BWS, SRS appears in IVF conceptuses more
often than predicted by random chance (Hattori et al., 2019). Additionally, ART-conceived SRS
patients have higher variability in methylation compared to spontaneously conceived SRS
individuals (Hattori et al., 2019). Because ART procedures occur in the developmental window
when the epigenome is reprogrammed, the epigenetic regulators responsible for maintaining
methylation imprints at IC1 may be perturbed, predisposing ART babies to a higher risk for SRS.

IC1 LoM can occasionally be caused by genetic lesions. SRS patients with IC1
hypomethylation also present with paternally inherited IC1 deletions (Abi Habib et al., 2017). A
BWS-related IC1 deletion that caused GoM on IC1 after maternal inheritance caused LoM on IC1
when paternally inherited (Kraft et al., 2019). As described in the hIC1Δ2.2 mouse model,
paternal transmission of the mutant hIC1 allele resulted in incomplete methylation of the paternal
IC1, recapitulating LoM in SRS (Figure 1.1A, hIC1Δ2.2 (Freschi et al., 2018)). The incomplete
establishment of methylation on the mutant IC1 may be due to the inability of the mutated allele
to be recognized by DNA methyltransferases during spermatogenesis and/or subsequent failure to
maintain the previously established methyl marks. Animals with a hypomethylated paternal ICR
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showed high H19 and low Igf2 expression, and were pre- and postnatally growth-restricted. The
liver and kidneys were more severely affected than other organs in this model, closely resembling
the organ-specific growth restriction in SRS.

The KRAB zinc finger protein ZFP57 is another factor that may affect DNA methylation
of the locus. ZFP57, which interacts with ICRs in a methylation-dependent manner, binds to
methylated CpGs in ICRs and protects them from genome-wide demethylation during the postfertilization reprogramming window (Li et al., 2008; Strogantsev et al., 2015). This binding
enables the preservation of parental allele-specific methylation in imprinted clusters. Previous
work suggested that ZFP57 was involved in the etiology of IC1 hypomethylation in SRS
(Hirasawa and Feil, 2008), in that loss-of-function mutation of ZFP57 resulted in mosaic
hypomethylation in many imprinted loci (Li et al., 2008; Mackay et al., 2008). Consistently,
Sparago et al. suggested that in the hIC1 mouse model (Hur et al., 2016), the paternally
transmitted hIC1 could not be properly methylated possibly because the inserted hIC1 sequence
lacked a ZFP57 binding site. They suggested that insertion of an additional ZFP57 binding site in
the hIC1 construct would enable ZFP57 to bind and protect paternally established methylation
(Sparago, Cerrato and Riccio, 2018). However, patients with transient neonatal diabetes mellitus
1 (TNDM1) caused by loss-of-function mutations of ZFP57 exhibited normal methylation of IC1
(Mackay et al., 2008; Boonen et al., 2013). Moreover, SRS patients with IC1 hypomethylation
were found to have no functional mutation of ZFP57 (Spengler et al., 2009). Although the role of
ZFP57 at IC1 remains to be determined, it is likely that other zinc finger proteins, such as the
recently described ZFP445, preserve DNA methylation and may harbor mutations in SRS patients
(Takahashi et al., 2019).
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Mutations in the H19/IGF2 cluster other than IC1 LoM are found in SRS patients.
Chromosomal structural variations in the H19/IGF2 enhancer region were reported in a group of
SRS patients (Grønskov et al., 2011). Paternally inherited genetic lesions disrupting the
interaction between the mesodermal enhancer and the IGF2 promoter resulted in delayed growth
in patients. In mice, the deletion of endodermal H19/Igf2 enhancers on the paternal allele led to
growth-restricted offspring (to 70% of that of wild-type at birth) and reduced Igf2 expression in
endodermal tissues such as liver and kidney (Figure 1.1C, EndoEnhΔ (Leighton et al., 1995)).
Additionally, paternally transmitted disruption of mesodermal H19/Igf2 enhancers resulted in
growth retardation (50% of wild-type at birth), repressing Igf2 expression in mesodermal tissues
including tongue and kidney (Figure 1.1C, Mnt (Davies and Reik, 2002)). The deletion of
mesodermal H19/Igf2 enhancers on the paternal allele also resulted in reduced Igf2 expression in
mesodermal tissues (Figure 1.1C, VM3 (Kaffer, Grinberg and Pfeifer, 2001)).

1.3.2. CDKN1C/KCNQ1OT1 cluster in SRS
A small number of SRS patients have mutations in the CDKN1C/KCNQ1OT1 cluster.
Maternally inherited activating mutations of CDKN1C were found in SRS patients (Table 1.1
(Brioude et al., 2013). A microduplication encompassing the CDKN1C/KCNQ1OT1 cluster, but
not the H19/IGF2 cluster, was found on the maternal allele of a SRS patient (Schönherr et al.,
2007). In a different SRS family, a microduplication of the CDKN1C/KCNQ1OT1 cluster resulted
in SRS only when maternally inherited (Bonaldi et al., 2011). A transgene modeling this
duplicated region led to the increased Cdkn1c expression in mice, together with growth reduction,
which was dependent on Cdkn1c dosage and lasted to adulthood (Andrews et al., 2007). This
mouse model also showed neonatal hypoglycemia, decreased body fat in adults (Van De Pette et
al., 2016) and behavioral abnormalities (McNamara et al., 2016), phenotypes that recapitulate
representative SRS features. Mice with deletion of paternal KvDMR1 exhibited biallelic
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expression of Cdkn1c and fetal growth retardation, further demonstrating the growth repressor
functions of Cdkn1c (Figure 1.2C, 2.8kb-KvDMR1Δ (Fitzpatrick, Soloway and Higgins, 2002)
and 3.6kb- DMRΔ (Mancini-DiNardo et al., 2006)). When the paternal Cdkn1c was activated due
to the truncation of the paternal Kcnq1ot1 transcript, mice exhibited growth deficiency (Figure
1.2C, YJ69 (Shin, Fitzpatrick and Higgins, 2008)). Transgenic overexpression of Phlda2 and
Slc22a18 resulted in placental growth retardation without involving a change in Cdkn1c
expression (Salas et al., 2004; Tunster, Tycko and John, 2010). Further research showed that the
increased Phlda2 expression contributed more to placental insufficiency and asymmetric growth
restriction (Tunster, Van De Pette and John, 2014). These results suggest that other genes in the
cluster can contribute the growth restriction phenotype of SRS.

1.3.3. mUPD11 and duplication of maternal chr11p15
Rarely, SRS patients have maternal UPD (mUPD) or maternal duplication of
chromosome 11p15 (Table 1.1, Figure 1.1D (Luk et al., 2016)). In mice, mUPD of mouse distal
chromosome 7, which includes the H19/Igf2 and Cdkn1c/Kcnq1ot1 clusters, resulted in growth
deficiency and perinatal lethality (Han, Szabó and Mann, 2010). In the presence of two maternal
distal chromosome 7 alleles, the maternally expressed genes are overexpressed and the paternally
expressed genes are silent. Accordingly, mUPD7 mice had loss of Igf2 and increased H19 and
Cdkn1c expression, which would result in severe undergrowth. To understand the source of the
perinatal lethality, the H19/Igf2 ICR and the Cdkn1c gene were deleted in mUPD7 mice. When
H19/Igf2 ICR was deleted on one allele of mUPD7 mouse, the pups were viable, but the growth
restriction persisted, albeit to a smaller extent. Here, Igf2 expression was restored to wild-type
levels, but Cdkn1c expression remained high. Deletion of Cdkn1c from the paternal allele of
mUPD7 mice restored embryonic weight to the wild-type level but lethality persisted. This
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demonstrates that excessive Cdkn1c expression was not responsible for mUPD7 lethality. Indeed,
IC1 and IC2 clusters may contribute uniquely to growth dysregulation in mUPD11 SRS patients.

1.3.4. mUPD7 and duplication of chr7 in SRS
5-10% of SRS patients are reported to have duplication (Monk et al., 2000, 2002;
Eggermann et al., 2012b) or mUPD on chromosome 7 (Yuan et al., 2016), where GRB10 resides
(Growth Factor Receptor Bound protein 10; also known as MEG1, Maternally Expressed Gene
1). SRS patients with mUPD7 are more likely to have verbal dyspraxia, learning difficulties,
myoclonus dystonia and autistic spectrum disorder compared to other SRS subgroups (Wakeling
et al., 2017a). GRB10 functions as a growth suppressor, binding to Insulin and IGF1 receptors to
inhibit the growth-promoting activity of IGF. Therefore, increased GRB10 in SRS patients can
result in an undergrowth phenotype. Grb10 is located on chromosome 11 in mouse, and the
somatic isoform is maternally expressed. Maternal duplication of mouse proximal chromosome
11, which includes the Grb10 locus, resulted in prenatal growth retardation (Miyoshi et al.,
1998). In contrast, paternal duplication of the same region resulted in growth enhancement,
proving that the allele-specific regulation of Grb10 expression is critical for normal development.
To note, Grb10 isoforms are expressed from different parental alleles in somatic and neuronal
tissues in mice. Absence of the paternal, brain-specific isoform of GRB10 might thus cause the
brain-specific phenotypes in mUPD7 patients.

Another imprinted gene implicated in SRS is located on chromosome 7q: MEST
(Mesoderm-specific Transcript; also known as PEG1, Paternally Expressed Gene 1). The MEST
promoter is methylated on the maternal allele, and MEST is expressed from the paternal allele
(Riesewijk et al., 1997). Several SRS patients with mild symptoms were reported to have mUPD
for chr7q (Hannula et al., 2001; Reboul et al., 2006; Eggermann et al., 2008) or a deletion on
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paternal 7q spanning MEST (Eggermann et al., 2012a). In mice, loss of Mest expression from the
paternal allele resulted in pre- and postnatal growth restriction (Lefebvre et al., 1998), suggesting
a growth regulatory role for MEST.

1.3.5. MLID: lesions on multiple loci in SRS
Multi-locus imprinting disturbances (MLID) exhibit multiple imprinted loci defects, in
addition to the locus primarily relevant to the patient’s symptoms (Sanchez-Delgado et al., 2016).
Up to 25% of BWS patients with IC2 LoM and 10% of SRS patients with IC1 LoM were
reported to have MLID (Azzi et al., 2009; Eggermann, Buiting and Temple, 2011). Although the
exact cause of MLID is unknown, some MLID patients carry defects in trans regulators such as
ZFP57 (Mackay et al., 2008), NLRP2 (Meyer et al., 2009), NLRP5 (Docherty et al., 2015) and
PADI6 (Begemann et al., 2018). Among these, deletion of oocyte-specific gene Nlrp5 (also
known as Mater) caused sterility in female mice, producing embryos developmentally arrested at
the two-cell stage (Tong et al., 2000). Females deficient for Nlrp2 were subfertile and produced
delayed and smaller offspring (Mahadevan et al., 2017), with more rapidly decreasing
reproductive rates, as one would expect with accelerated aging (Kuchmiy et al., 2016). Mice do
not have an ortholog of NLRP7 and therefore, defects in NLRP7 could not be modeled. Overall, it
would be important to understand the roles of these trans regulators that may be crucial for
establishing and maintaining DNA methylation on multiple imprinted loci.

1.4. Conclusions
As described in this chapter, mouse models have been widely utilized to understand how
genomic imprinting is established, maintained and inherited in humans. Although previous
studies showed that various epimutations on the H19/IGF2 imprinted cluster are associated with
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BWS and SRS, how different molecular subtypes lead to specific pathological features remains
poorly understood. Furthermore, certain epigenetic mutations on the human H19/IGF2 cluster are
harder to be phenocopied in mice. For example, modeling pUPD11 in mice has been challenging
due to embryonic lethality. This prenatal death is caused by loss of expression of the imprinted
Ascl2 gene, which is not imprinted in humans (Westerman et al., 2001; Miyamoto et al., 2002;
Rentsendorj et al., 2010). Additionally, the mosaicism observed in human pUPD11 patients is not
evident in mice. Together, these factors complicate the modeling of human pUPD11, which is a
significant cause of BWS.
In chapter 2, human induced pluripotent cell (hiPSC) model was utilized to overcome
such limitations. Skin fibroblasts collected from BWS individuals with pUPD11 were
reprogrammed into isogenic hiPSC clones. The strength of this system is the preserved
pathological genetic environment. This eliminates the need to manipulate the genome to achieve
the desired mutations and possible off-target effects of gene editing. Another advantage of the
system is that hiPSCs can be differentiated into clinically relevant tissues that are not readily
accessible in human BWS patients. In this dissertation, hiPSCs were differentiated into a hepatic
lineage to generate pUPD11 and non-pUPD11 hepatocytes. Through analyzing their
transcriptomic profiles, this study identified signaling pathways that are potentially associated
with the higher occurrence of hepatoblastoma and overgrowth in BWS individuals.
In chapter 3, various mouse models mimicking SRS-like phenotypes were utilized to
understand the effect of H19/Igf2 dysregulation on embryonic development in different tissues.
Examining the tissue-specific function of H19 and Igf2 is crucial to comprehend the organspecific growth dysregulation of BWS and SRS. This study identifies the heart and placenta as
organs that are most susceptible to H19 overexpression in the context of Igf2 depletion, and
suggests that H19 and Igf2 may be important mediators of a cardiac-placental axis. Overall, both
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studies in this dissertation aim to describe detailed roles of H19 and IGF2 in disease-relevant
tissue types, utilizing different types of research models.

1.5. Contributions
This chapter contains direct quotes and figures from Chang and Bartolomei, 2020.
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Figure 1.1. H19/IGF2 Imprinted Locus.
(A) Human H19/IGF2 cluster. On the maternal allele, CTCF binds to the unmethylated IC1 and
insulates the IGF2 promoter from the downstream enhancers, enabling H19 expression. The
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methylated paternal IC1 silences the paternal H19 allele and allows IGF2 expression. IGF2 is
expressed from multiple promoters. MIR675 is located within the first exon of H19, whereas
MIR483 is encoded within the second to last intron of IGF2. The BWS-related mutation
(hIC1Δ2.2), which was introduced in the humanized IC1 allele in mice, is shown at the bottom of
the panel. (B) Mouse H19/Igf2 cluster. The H19/Igf2 ICR is smaller in size and has fewer CTCF
binding sites compared to human IC1, but the imprinting mechanism, detailed in (A), is
conserved between two species. (C) Summary of the mouse models described in this dissertation.
Striped boxes indicate deletions and solid-filled boxes indicate mutations. (D) Simplified
depiction of uniparental disomy (UPD). Sizes in kb are approximate and figures are not drawn to
scale.
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Figure 1.2. CDKN1C/KCNQ1OT1 Imprinted Locus.
(A) Human CDKN1C/KCNQ1OT1 cluster. On the maternal allele, IC2, which includes the
transcription start site of KCNQ1OT1, is methylated. Thus, the maternal KCNQ1OT1 is
repressed, allowing the expression of maternal allele-specific linked genes such as KCNQ1 and
CDKN1C. On the paternal allele, IC2 is unmethylated and KCNQ1OT1 is transcribed, silencing
the linked imprinted genes on the paternal allele. (B) Mouse Cdkn1c/Kcnq1ot1 cluster. Note that
IC2 is designated as KvDMR1 in mouse. The methylation on the Cdkn1c promoter and gene body
is acquired post-fertilization, and is absent in human (Bhogal et al., 2004). (C) Mouse models
described in this dissertation. Striped boxes indicate deletions and filled triangles indicate
insertions of truncation cassettes. Figures are not drawn to scale.
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Figure 1.3. Establishment of DNA Methylation at the CDKN1C/KCNQ1OT1 imprinted
locus.
(A) The transcription of Kcnq1 in mouse oocytes is postulated to establish maternal allelespecific methylation on KvDMR1, which silences maternal Kcnq1ot1 expression in the progeny.
The allele-specific regulation of this cluster is conserved in humans. (B) Truncating the maternal
Kcnq1 transcript in mice (YJ11(Singh et al., 2017)) resulted in hypomethylation on the maternal
KvDMR1. In humans, maternally inherited mutations, which disrupt KCNQ1 transcription, are
hypothesized to disrupt the establishment of methylation on maternal IC2, which can lead to LoM
on IC2 in the progeny (Niemitz et al., 2004; Beygo et al., 2019; Valente et al., 2019). See text for
details.
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Table 1.1. BWS and SRS Genetic Lesions and Associated Recent References.
a

(Eggermann et al., 2014)

b

(Eggermann, Buiting and Temple, 2011).

c

(Wesseler, Kraft and Eggermann, 2019)
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CHAPTER 2. HUMAN INDUCED PLURIPOTENT STEM CELL
MODEL FOR PUPD11
2.1. Background
Genomic imprinting, the regulation of genes in a parent-of-origin-specific manner, plays
an essential role in normal mammalian development. Imprinted genes are typically clustered and
regulated by imprinting control regions (ICRs) or differentially methylated regions (DMRs),
which are methylated in a parental allele-specific manner. Human disorders displaying aberrant
growth, metabolic, and/or neurological phenotypes may be associated with genetic and/or
epigenetic alterations at imprinted loci (Kalish, Jiang and Bartolomei, 2014). BeckwithWiedemann syndrome (BWS) is the most common imprinting disorder, affecting at least
1/10,340 individuals (Mussa et al., 2016). Clinical presentation involves multiple organ
overgrowth including the tongue (macroglossia), the pancreas (hyperinsulinism), and the liver
and kidneys. In some cases, organ overgrowth manifests as embryonal tumors, most commonly
hepatoblastoma and Wilms tumor (Wang et al., 2020).

BWS is due to genetic and/or epigenetic changes of two conserved clusters of imprinted
genes on chromosome 11p15.5. This region contains the imprinted genes H19, a maternallyexpressed long non-coding RNA, and IGF2, a paternally-expressed fetal growth factor. H19 and
IGF2 are coordinately regulated by an ICR located between the two genes, designated as
H19/IGF2:IG DMR or IC1 (Brioude et al., 2018). IC1 is DNA methylated on the paternal allele
and is unmethylated on the maternal allele, where it serves as a CTCF-dependent insulator that
engages with tissue-specific enhancers. The adjacent imprinted cluster regulated by the
maternally DNA methylated CDKN1C/KCNQ1 ICR (KCNQ1OT1:TSS DMR or IC2), includes
the maternally expressed gene CDKN1C, a cell cycle inhibitor. Paternal uniparental isodisomy for
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part of chromosome 11 (pUPD11) occurs in about 20% of BWS cases, resulting in gain of
methylation at IC1, loss of methylation at IC2, and subsequent dysregulation of the imprinted
genes associated with BWS (Brioude et al., 2018). pUPD11 occurs when, post-zygotically, part
of maternal chromosome 11 is lost in a single cell and the normal chromosome complement is
preserved through a rescue by the corresponding paternal region (Kotzot, 2008). This rescue
event causes both chromosome 11s to have the paternal epigenotype and the clinical features of
BWS.

Mouse models have provided insights into imprinting mechanisms. However, BWS
modeling in mouse has limitations. Mice with mutations at the endogenous IC1 (designated as
ICR in mouse) or IC2 (designated as KvDMR1 in mouse) were not able to fully exhibit the
corresponding BWS phenotypes. For example, loss of methylation at the maternal KvDMR1 were
lethal in mice (Singh et al., 2017), although BWS is fully viable in human. Mice with cdkn1c
mutation showed a low survival rate together with fetal overgrowth, which was ultimately
reversed in late gestation (Yan et al., 1997; Tunster, Van De Pette and John, 2011), failing to
demonstrate the BWS phenotype. In mice with mutations in the H19/Igf2 ICR, there were
limitations in examining the human BWS mutations this is at least partially due to the divergent
ICR sequences between mouse and human (Engel, Thorvaldsen and Bartolomei, 2006b;
Ideraabdullah et al., 2014). Consistently, the human IC1 sequence knocked-in to the orthologous
mouse locus only partially recapitulates imprinting in mouse (Hur et al., 2016; Freschi et al.,
2018). Thus, human models are necessary to investigate the BWS mechanisms that contribute to
observed overgrowth and cancer predisposition.

Common origins of BWS, such as pUPD11, cannot be easily engineered in human cell
lines. In most cases of BWS, including pUPD11, the genetic or epigenetic changes arise post30

zygotically resulting in cellular mosaicism (Kotzot, 2008). Thus, human cell-based models
consisting of pure populations of genetically matched diseased or unaffected cells provide an
excellent means to investigate epigenetic and/or transcriptional mechanisms underlying BWS. To
this end, induced pluripotent stem cells (iPSCs) are a valuable technology to study human disease
showing clinical features in tissues that are not readily accessible (Unternaehrer and Daley,
2011). Rare and common diseases are increasingly being modeled using iPSCs, including other
imprinting disorders such as Angelman syndrome and Prader-Willi syndrome (Chamberlain et
al., 2010; Cruvinel et al., 2014; Stelzer et al., 2014; Fink et al., 2017; Kim et al., 2019).

Here, we present the derivation of the first BWS iPSC lines from pUPD11 patient
samples. We show that pUPD11 and non-pUPD11 iPSC lines can be derived from mosaic
samples. Additionally, to evaluate the alterations in gene expression in a clinically relevant tissue
type, these lines were differentiated into hepatocyte lineages.

2.2. Results
2.2.1. Derivation of iPSCs from pUPD11 patient fibroblasts
Skin samples from two male patients were collected during surgical procedures and used
to grow fibroblast cell lines for reprogramming. pUPD11 breakpoints as well as extent of
mosaicism of pUPD11 for all patients were determined using genome-wide single-nucleotide
polymorphism (SNP) microarray analysis (Figures 2.1 and Supplemental Figure 2.1). To
demonstrate that two populations of cells, designated isogenic pUPD11 and non-pUPD11 iPSCs,
can be derived from mosaic fibroblast cell lines, we reprogrammed fibroblasts from these patients
using two distinct reprogramming strategies. As a sex- and cell-type- matched control, we
reprogrammed one male fibroblast cell line (IMR91). The iPSC colonies were picked, expanded
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for at least three passages and counted (Figures 2.1 and Supplemental Figure 2.1, Table 2.1). All
fibroblast samples and iPSC lines had a normal karyotype (data not shown). Further
characterization showed that the iPSCs expressed similar levels of stemness cell surface markers
and all three germ layer lineage markers upon differentiation into embryoid bodies (EBs) as
measured by quantitative real-time PCR (qRT-PCR) (Supplemental Figures 2.3A and 2.4A-E),
regardless of the reprogramming strategy or the extent of pUPD11 in the parental fibroblasts. To
determine which iPSC lines had pUPD11 versus biparental chromosome 11, we used
microsatellite fragment analyses or restriction fragment length polymorphisms (Supplemental
Figure 2.5). Notably, the percent of pUPD11 iPSC lines derived relative to the total number of
lines was reflective of the percent pUPD11 in the initial fibroblast samples (Figure 2.1). No
pUPD11 iPSC lines could be obtained from a third patient with a low level of pUPD11 in their
fibroblasts (data not shown). These results demonstrate that pUPD11 and non-pUPD11 iPSC
lines can be derived from a mosaic patient fibroblast sample.

2.2.2 DNA methylation pattern of pUPD11 iPSCs
pUPD11 iPSCs display the expected DNA methylation pattern at IC1 and IC2
DNA methylation status at IC1 and IC2 is the most widely used molecular marker to
diagnose BWS (Brioude et al., 2018). Thus, it is essential that iPSC lines designed to model BWS
display the expected methylation status at both ICRs (Figure 2.2A). To determine if iPSC lines
maintain the DNA methylation status of the parental fibroblasts, IC1 and IC2 methylation levels
were measured. For IC1 methylation analyses, we performed pyrosequencing for patient 1. Due
to the presence of SNPs in the pyrosequencing primer binding site for patient 2’s cell lines,
combined bisulfite restriction analysis (COBRA) was used to evaluate methylation. IC2
methylation for all lines was analyzed using COBRA. Because pUPD11 iPSC lines have two
copies of paternal IC1, they exhibited ~100% methylation as expected, and non-pUPD11 iPSC
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lines displayed the expected ~50% methylation resulting from the unmethylation maternal and
methylated paternal alleles (Figures 2.2B and Supplemental Figure 2.6). To validate the COBRA
results, IC1 methylation in the patient 2 fibroblasts and select non-pUPD11 and pUPD11 iPSC
lines were determined using bisulfite treatment followed by direct sequencing. The sequencing
results replicated the COBRA results (Supplemental Figure 2.6). Several studies have reported
stochastic aberrant DNA methylation at IC1 in mouse and human pluripotent stem cells (Nishino
et al., 2011; Nazor et al., 2012; Sun et al., 2012; Takikawa et al., 2013). Yet, different parental
cell sources, culture conditions, and passaging techniques used in the reprogramming experiments
make it difficult to link a particular factor to the origin of such anomalies (Nazor et al., 2012). To
investigate whether this phenomenon also occurs in our cell lines, select patient non-pUPD11 and
pUPD11 iPSC lines were cultured over prolonged periods. All iPSC lines maintained stable
methylation patterns in later passages (Figure 2.2C and data not shown), demonstrating that the
reprogramming and/or culture conditions for iPSC lines did not perturb methylation. Finally, we
evaluated methylation at IC2. Because the paternally inherited IC2 is normally unmethylated, all
pUPD11 iPSC lines showed no detectable methylation at IC2 (Figure 2.2D and data not shown),
whereas non-pUPD11 iPSC lines showed normal methylation. Therefore, IC1 and IC2
methylation status is appropriate for the parent-of-origin and maintained after the derivation and
culture of iPSC lines.

Because DNA methylation exhibited the expected patterns in the non-pUPD11 and
pUPD11 iPSC lines, we evaluated expression of imprinted genes in the pUPD11 region. Given
the timing of H19 and Igf2 expression in development (Lee, Pintar and Efstratiadis, 1990; Poirier
et al., 1991), expression levels were analyzed in undifferentiated and differentiated iPSC lines by
qRT-PCR. To examine H19 and IGF2 expression in differentiated cells, the iPSC lines were
cultured as embryoid bodies (EBs) (Supplemental Figure 2.3A). As expected, low level
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expression was observed in undifferentiated iPSCs (Supplemental Figure 2.3B). The pUPD11
EBs displayed no expression of H19, whereas non-pUPD11 EBs expressed H19. Furthermore,
pUPD11 EBs expressed higher levels of IGF2 compared to the non-pUPD11 EBs (Supplemental
Figure 2.3B). These results demonstrate that H19 and IGF2 gene expression appropriately
reflected the non-pUPD11 versus pUPD11 status of the iPSC lines.

2.2.3 Transcriptome profiling of hepatocyte lineages differentiated from iPSCs
Differentiated iPSCs demonstrate pathway dysregulation
To elucidate the pathways involved in overgrowth and cancer formation in BWS, the
iPSC lines were differentiated into hepatocyte lineages, a lineage affected by overgrowth leading
to hepatomegaly and cancer in the form of hepatoblastoma in BWS. Hepatocyte lineage
differentiation was performed as previously described (Gadue et al., 2006; Ogawa et al., 2013,
2015; Mills et al., 2014; Holtzinger et al., 2015). Only iPSC lines expressing >90% stemness
markers, SSEA3/4 and Tra-1-60/81, were used for differentiation and only iPSC lines coexpressing >90% CXCR4 and c-kit definitive endoderm markers at day 7 were continued for
hepatic specification and maturation (Table 2.2). AFP and ATT were monitored during
differentiation (Table 2.2). We then performed RNA sequencing (RNA-Seq) on the control,
pUPD11 and non-pUPD11 hepatocytes to characterize their expression profiles. Samples were
collected on days 20 (D20) and 24 (D24) post-differentiation and the latter cells were purified by
fluorescence-activated cell sorting (FACS) for cell surface expression of ASGR1, a hepatocyte
maturation marker for hepatocyte differentiation (Peters et al., 2016) (Supplemental Figures 2.4FJ and 2.7). To determine the extent of differentiation of these hepatocyte populations, expression
levels for six liver gene markers (ALB, ASGR1, CPS1, HGD, HNF1A, HNF4A) (Pashos et al.,
2017) were assessed (Supplemental Figure 2.7). Expression levels were higher in the D24 sorted
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cells (Supplemental Figure 2.7), indicating successful differentiation and purification of mature
liver-like hepatocytes from the pUPD11, non-pUPD11 iPSC, and control lines.

To evaluate the maintenance of imprinting in these D24 hepatocytes, we assessed the
expression of genes regulated by the two imprinted domains on chromosome 11p15.5 in the
RNA-Seq data. Expression levels of IGF2 and KCNQ1OT1 were significantly increased and
CDKN1C, KCNQ1, and H19 expression was significantly decreased in pUPD11 lines compared
to non-pUPD11 lines and control lines, suggesting that imprinting was maintained postreprogramming and differentiation in our model system (Supplemental Figure 2.8).

With the integrity and maintenance of imprinting established in undifferentiated and
differentiated lines, we examined the overall transcriptional profile of the D24 sorted hepatocytes.
PCA plots with coloring by patient source revealed distinct clustering of the control, Patient1, and
Patient2 clones (Supplemental Figure 2.9). Statistically, DESeq2 (Love, Huber and Anders, 2014)
revealed 362 genes were upregulated and 170 downregulated when comparing BWS-derived
iPSC lines to control lines (Chang et al., 2020). Furthermore, 322 genes were upregulated and
153 downregulated when comparing pUPD11 clones to that of both non-pUPD11 and control
lines. Of these, 106 genes overlap between the group comparisons, indicating not only a unique
transcriptional profile of pUPD11 cells, but also a BWS-specific profile. This analysis was
supported by Gene Set Enrichment Analysis (GSEA) (Mootha et al., 2003; Subramanian et al.,
2005). This analysis was similarly performed to compare all BWS clones to control clones as well
as pUPD11 clones compared to grouped non-pUPD11 and control clones. Gene sets related to
growth including PI3K/AKT/mTOR signaling, GO:0032869 response to insulin stimulus, and
GO:0008283 cell proliferation demonstrated differential enrichment in BWS and pUPD11 clones
(Table 2.3). Representative enplots for GO:0008283 cell proliferation, the gene set with the most
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significant association (Table 2.3) are included in Supplemental Figure 2.10. Genes from all
aforementioned pathways displaying differential expression are reported (Figure 2.3B). These
results indicate a transcriptional profile specific to pUPD11 cells, as well as a distinct
transcriptional profile common to all cell derived from BWS patients including the non-pUPD11
cells (Chang et al., 2020).

We performed similar analysis to test for differential enrichment of liver cancer
expression profiles comparing both BWS to control and pUPD11 to grouped non-pUPD11 and
control clones (Table 2.3). Genes demonstrating differential expression from this GSEA are
included in Figure 2.3B. We next sought to understand the relationship among these differentially
expressed growth genes as a contributory factor in BWS overgrowth and cancer predisposition.
To achieve this, we used STRING (Szklarczyk et al., 2019) to analyze the interactions, coexpression, and co-regulation between PI3K/AKT/mTOR, insulin, and cell proliferation signaling
genes that were up- or down-regulated in the pUPD11 clones compared to non-UPD11 clones and
controls (Figure 2.4). Clusters of nodes highlighted in green are largely components of insulin
signaling and connect to IGF2 (Figure 2.4). Blue and yellow cluster members function in cell
proliferation, with the yellow cluster specifically regulating cell cycle progression including
CDKN1C (Figure. 2.4). Genes represented by red nodes do not cluster specifically with any of the
other groups and tend to have weaker connections with central factors, as represented by the
lighter gray color and dotted rather than solid line (Figure 2.4). While IGF2 and CDKN1C are
part of the pUPD11 region, many of the factors represented in this network are located on other
chromosomes, such as the central genes FOXO1 on chromosome 8 and MYC on chromosome 13,
demonstrating a complex, interconnected regulatory mechanism associated with BWS acting on
these pathways from pUPD11 BWS cells to create the overgrowth phenotype as well as potential
cancer predisposition.
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2.3. Discussion
Here, we report the establishment of a human iPSC model system for BWS. We derived
both pUPD11 and non-pUPD11 iPSC lines from two BWS patient fibroblast samples that had
distinct pUPD11 regions and differing levels of mosaicism for pUPD11. For each reprogramming
experiment, the non-pUPD11 iPSC-derived lines serve as isogenic internal controls for the
pUPD11-derived iPSC lines, having the same genetic background except for the pUPD11
regions. The use of isogenically matched iPSC lines to study human diseases is a valuable
resource as it diminishes the potential genetic variability between individuals. To our knowledge,
this is the first human iPSC model of BWS providing a valuable tool to study the mechanisms of
IC1 and IC2 imprinting in BWS.

Importantly, we show that the proportion of the pUPD11 iPSC lines obtained relative to
the total number of iPSC lines reflected the percent of pUPD11 cells in the patient samples. Thus,
we demonstrated that both cell types can be derived from a mosaic patient sample. In addition,
the results may suggest that during reprogramming, the pUPD11 cells may not have growth
advantages, even though the paternally-expressed growth-promoting gene, IGF2, is
overexpressed and the maternally-expressed growth-suppressing genes, CDKN1C and H19, are
repressed in these cells. Lack of a growth advantage is likely due to relatively low expression of
the genes during iPSC reprogramming, as H19 and IGF2 expression was low in the
undifferentiated iPSC lines and increased in the differentiated lines.

We successfully differentiated both pUPD11 and non-pUPD11 iPSC into hepatocyte
lineages, providing a new research tool for modeling BWS in cell types not easily accessible in
BWS patients. Once differentiated, we assessed the transcription profile of these cells by RNA37

Seq. Interestingly, statistical comparison of BWS clones or pUPD11 clones compared to the other
samples produced approximately 500 and 400 differentially expressed genes, respectively, but
only about 100 of these genes overlapped (Figure 2.3A). These data, and most specifically these
100 commonly differentially expressed genes, suggest that the non-pUPD11 lines transcriptional
profile may be the result of epigenetic memory from the previous influence of the adjacent
pUPD11 cells in the BWS patient.

Differential enrichment of PI3K/AKT/mTOR, insulin, and cell proliferation signaling
factors was identified through GSEA (Table 2.3, Figure 2.3B and Supplemental Figure 2.10).
Genes identified by liver cancer profiles were also differentially expressed in the BWS
hepatocytes (Figure 2.3B, Table 2.3). As BWS is an overgrowth and cancer predisposition
syndrome, we hypothesized that growth dysregulation underlies this cancer profile and, therefore,
focused our attention on the growth genes in pUPD11 lines for network analysis (Figure 2.4). We
observed gene clusters related to IGF2 insulin signaling and CDKN1C cell cycle regulation as a
result of the pUPD11 phenotype (Figure 2.4). We also observed a number of genes up- or downregulated that are not located within the pUPD11 region. In the middle of the STRING diagram,
transcription factors FOXO1 and MYC create connectivity between the blue cell proliferation,
yellow cell cycle, and green insulin signaling clusters (Figure 2.4). Both of these genes were
under-represented in our pUPD11 samples. While MYC is most often considered for its oncogenic
properties, it has also been observed to increase cellular sensitivity to apoptotic signals
(Prendergast, 1999). FOXO1 acts as a tumor suppressor and FOXO transcription factors have
been found to negatively regulate MYC signaling (Bouchard et al., 2007; Peck, Ferber and
Schulze, 2013; Wang, Zhou and Graves, 2014). Further investigation into the regulation and
function of these factors in overgrowth and tumorigenesis in BWS are certainly warranted by
these findings.
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In conclusion, we have demonstrated that the BWS human iPSC model system derived in
the current study exhibits the anticipated epigenetic and transcriptional characteristics of
pUPD11. Importantly, DNA methylation was stably maintained at the ICRs within the pUPD11
region in the iPSC lines over prolonged culture. This is critical as we demonstrated further
differentiation of these cell lines into clinically relevant cell types, hepatocyte lineages to study
mechanisms underlying BWS. Investigation of these differentiated cells demonstrated complex
interactions among genes in insulin, cell cycle, and cell proliferation pathways suggestive of a
possible mechanistic underpinning of the complex overgrowth and cancer predisposition
phenotype in BWS. Thus, these cell lines serve as a model to further investigate BWS.

2.4. Contributions
This chapter contains direct quotes and figures from Chang et al., 2020. Stella Hur and
Joanne Thorvaldsen designed the study, performed and analyzed experiments, and wrote the
manuscript. Suhee Chang performed experiments and wrote the manuscript. Natalie S. Sobel
Naveh analyzed data and wrote the manuscript. Deborah L. French, Alyssa L Gagne, Chintan D.
Jobaliya performed experiments and analyzed data. Montserrat C. Anguera analyzed data and
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Figure 2.1. Summary of reprogramming in this study.
A schematic illustrating chromosome 11 with relative locations of IC1 and IC2 as well as regions
of pUPD11 (open rectangles) of each pUPD11 fibroblast cell line (Patient 1, 2). pUPD11 break
points are indicated next to regions of pUPD11 (Human Genome Build 37, hg19, 2009). Percent
pUPD11 in the parental fibroblasts, total number of iPSC clones derived from each fibroblast line
and, from patient fibroblasts, the number of non-pUPD11 and pUPD11 iPSC clones derived. NA:
not applicable.
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Figure 2.2. Methylation at BWS-related imprinting control regions in iPSC clones.
(A) The imprinted region on chromosome 11p15. IC1 is methylated on the paternal allele, leading
to the paternal allele-specific expression of IGF2 and the maternal allele-specific expression of
H19. IC2 is methylated on the maternal allele; KCNQ1 and CDKN1C are expressed from the
maternal allele while KCNQ1OT1 is expressed from the paternal allele. Black closed circles
indicate the allele-specific methylation on each ICR. Arrows indicate the allele-specific
expression of the genes. The small black bars below the region indicate primer location for the
methylation assays (a: COBRA and direct sequencing of cloned bisulfilte treated DNA b:
pyrosequencing, c: COBRA). Figure is not drawn to scale. (B) Methylation at IC1 measured by
pyrosequencing (in IMR91 and patient 1 cell lines) and COBRA (in patient 2 cell lines). (C)
Methylation at IC1 in select patient 1 iPSCs during extended culture. Bars are grouped by clones.
‘p’ indicates the passage number. (D) Methylation at IC2 measured by COBRA. (B-D) Each
graph includes results from the parental fibroblast cell line (grey bar) and iPSC lines derived from
the respective fibroblast cell line (black bars). pUPD11 clones are highlighted in grey boxes. Fib
= fibroblasts.
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Figure 2.3. RNA-Seq expression profiles in control, non-UPD11, and pUPD11 patient cell
lines.
(A) Venn diagram demonstrating the statistically significant differentially expressed genes (DGE)
identified by DESeq2 when comparing all non-pUPD11 and pUPD11 patient-derived lines to
control hepatocytes (blue oval) and those identified when comparing the pUPD11 iPSC lines
from both patients to the non-pUPD11 lines from both patients grouped with the control lines (red
oval). (B) Heatmap of transformed expression data for growth and liver cancer genes
differentially expressed across groups identified through GSEA.
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Figure 2.4. Network of interactome among differentially expressed genes in BWS iPSC lines
differentiated into hepatocyte lineages.
pUPD11 lines were compared to non-UPD11 and control lines. Genes were identified by GSEA
enrichment. Green clusters of nodes are largely components of insulin signalling and connect to
IGF2. Cell proliferation pathways are indicated by blue and yellow clusters, with the yellow
cluster specifically regulating cell cycle progression including CDKN1C. Edges between gene
nodes indicate confidence in the interaction by the intensity of the line. Kmeans clustering was set
to 8 and disconnected nodes were hidden.
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Supplemental Figure 2.1. Single nucleotide polymorphism array data.
SNP microarray analysis to determine extent of UPD. (A) Human chromosome 11 ideogram
based on hg19. Red box indicates location of imprinted domains IC1 and IC2. (B) LogR Ratio
and B-allele frequencies in skin from Patient1. (C) LogR Ratio and B-allele frequencies in skin
from Patient2.
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Supplemental Figure 2.2. Phase-contrast images of human iPSC colonies.
Scale bars = 100𝜇m.
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Supplemental Figure 2.3. Expression of germ lineage markers, H19, and IGF2 in iPSC lines
and embryoid bodies (EBs) for representative derived lines.
(A) Expression of germ lineage markers in the EBs measured by qRT-PCR. Endoderm markers:
AFP and GATA4; mesoderm markers: HAND1 and RUNX2; ectoderm markers: NACM1 and
FGF5. Expression in the EBs was normalized to expression in the counterpart iPSC lines (set to
1). Y-axis is in log base 10 scale. (B) Expression of H19 and IGF2 in iPSC lines and EBs
measured by qRT-PCR. H19 expression (red bars) and IGF2 expression (blue bars) in iPSC lines
and EBs. Note scale breaks on the y-axes. Bars representing H19 and IGF2 expression in
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pUPD11 iPSC lines, H19 expression in pUPD11 EBs and H19 expression in Patient 1 nonpUPD11 are too small to be seen.
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Supplemental Figure 2.4. FACS data.
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FACS data demonstrating stemness for representative lines (A) Patient1 non-pUPD11 line. (B)
Patient1 pUPD11 line. (C) Patient2 non-pUPD11 line. (D) Patient2 pUPD11 line. (E) IMR91
line. FACS data demonstrating hepatocyte differentiation for representative lines (F) Patient1
non-pUPD11 line. (G) Patient1 pUPD11 line. (H) Patient2 non-pUPD11 line. (I) Patient2
pUPD11 line. (J) IMR91 line.

Supplemental Figure 2.5. Microsatellite fragment analysis.
(A) Patient 1 samples.The paternal allele has two distinct lower bands while the maternal allele
has three bands (B) Patient 2 samples. The paternal allele has one upper band and the maternal
allele has two lower bands. P=patient skin sample, M= maternal blood sample F= paternal blood
sample (F), U= pUPD11 clones, and N=non-pUPD11 iPSC clones.
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Supplemental Figure 2.6. IC1 methylation of Patient 2 fibroblasts and iPSCs.
Bisulfite treatment followed by direct sequencing was performed at IC1 on Patient 2 fibroblasts
and iPSC clones (non-pUPD11 and pUPD11). See Figure 2.2A for location of IC1 primers used
for cloning of bisulfite treated DNA.
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Supplemental Figure 2.7. Hepatocyte marker expression in D20 and D24 differentiated
cells.
Boxplot of transformed expression values for differentiated cells on day 20 (D20) and ASGR1sorted day 24 (D24) are displayed. Based on RNAseq data for the nine iPSC lines. p-values
determined by T-test indicated by *<0.05, **<0.01,***<0.001.
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Supplemental Figure 2.8. Expression of imprinted genes from chromosome 11p15
centromeric and telomeric domains (see Figure 2.2A) in hepatocyte lineages from
differentiated iPSC lines.
Boxplots of transformed RNA-Seq expression of A) CDKN1C B) KCNQ1 C) KCNQ1OT1 D)
IGF2 and E) H19 for control and non-pUPD11 lines or pUPD11 lines. p-values determined by Ttest indicated by *<0.05.
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Supplemental Figure 2.9. Principal component analysis of gene expression profiles of D24
differentiated hepatocytes.
Coloring indicates patient source of differentiated iPSC lines. Plot generated using PCAtools
(10.18129/B9.bioc.PCAtools).

Supplemental Figure 2.10. Representative GSEA enplots.
Enrichment test for Cell_Proliferation_GO_0008283 comparing A) Control (C) to all BWS
clones (REST) and B) pUPD11 (UPD) clones to grouped non-pUPD11 and control (REST).

52

Table 2.1. Percentage of clones in the iPSC line derivation.

Number

Total

% clones

Non-UPD

UPD

% non-

% UPD

of clones

number of
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Table 2.2. iPS line labels, genotype, and differentiation markers for hepatocyte
differentiation.

Patient

Genotype and

Day 14

Day 20

Day 24

designation

AFP/AAT

AFP/AAT

AFP/AAT

Patient1

pUPD11 clone1

96.5/30.7

97.6/76.7

98/91.5

Patient1

pUPD11 clone2

89/1.02

93.6/73.2

94.1/90.1

Patient1

pUPD11 clone3

74.6/33.4

67.2/77.3

82.5/81.6

Patient1

non-pUPD11 clone 1

98.5/24

95.3/64.5

94.2/67.8

Patient2

pUPD11 clone1

96.6/14

96.6/85.8

96.3/87.2

Patient2

non-pUPD11 clone 1

97.1/30.2

95.4/51.4

95.2/79

control

IMR91 clone 1

97.7/37.6

95.4/68.1

96.9/89.7

control

IMR91 clone 2

88.6/8.82

78.1/59.3

86.6/54
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control

CHOPWT14

98.3/59.4

95.5/95.5

98.3/94.2

Table 2.3. GSEA pathway analysis scores

CHIANG_LIVER_CANCER SUBCLASS_PROLIFERATION_UP
CHIANG_LIVER_CANCER SUBCLASS_PROLIFERATION_DN
CAIRO_HEPATOBLASTOMA_UP
CAIRO_HEPATOBLASTOMA_DN
CELL_PROLIFERATION_GO_0008283
HALLMARK_PI3K_AKT_MTOR_SIGNALING
GO_CELLULAR_RESPONSE_TO_INSULIN_STIMULUS
PACHER_TARGETS_OF_IGF1_AND_IGF2_UP

BWS vs Control
pUPD11 vs non-pUPD11 and Control
Normalized
Normalized
Enrichment Enrichment Nominal FDR q- FWER Enrichment Enrichment Nominal FDR q- FWER
Score
Score
p-value value
p-value Score
Score
p-value value
p-value
0.560
1.160
0.343 0.692 0.595
0.400
0.890
0.624 0.684 0.926
-0.390
-0.980
0.489 0.633 0.819
-0.330
-0.870
0.704 0.692 0.935
-0.220
-0.990
0.425 0.798 0.807
-0.300
-1.370
0.054 0.151 0.206
-0.360
-1.100
0.301 1.000 0.682
-0.340
-1.010
0.402 0.665 0.847
-0.300
-0.210

-1.080
-0.950

0.245
0.587

0.864
0.546

0.722
0.837

-0.380
-0.210

-1.370
-0.990

0.023
0.470

0.293
0.565

0.198
0.861

0.200
0.270

1.030
0.630

0.405
0.920

0.641
0.956

0.801
0.989

0.180
-0.570

0.930
-1.270

0.649
0.120

1.000
0.232

0.888
0.391
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CHAPTER 3. ROLE OF H19/IGF2 DYSREGULATION IN SRS-LIKE
MOUSE MODELS
3.1. Background
Genomic imprinting is a mammalian-specific phenomenon where a small number of
genes is expressed in an allele-specific manner. Functionally, imprinted genes have central roles
in development and growth in both humans and mice. Additionally, proper gene dosage of most
imprinted genes is essential for normal development. Human chromosome 11 and the orthologous
region on mouse chromosome 7 harbor two jointly controlled growth regulators with opposing
functions; H19 long noncoding RNA (lncRNA) and Insulin-like Growth Factor 2 (IGF2). These
two imprinted genes share an imprinting control region (ICR), a cis-regulatory element located
between two genes, which is essential for their allele-specific expression, as well as enhancers
located downstream of H19. The H19/IGF2 ICR, which is designated as IC1 in humans, binds
CTCF on the maternal allele, forming an insulator and enabling H19 exclusive access to the
shared enhancers (Figure 3.1A). On the paternal allele, the H19/IGF2 ICR is methylated, which
prevents CTCF from binding and an insulator from forming. Consequently, IGF2 usurps the
shared enhancers and H19 is repressed on the paternal allele. Ultimately, allele-specific ICR
methylation facilitates allele-specific expression of H19 and IGF2 with one copy of H19
expressed from the maternal allele and one copy of IGF2 expressed from the paternal allele.

Dysregulation of the H19/IGF2 cluster is associated with two growth disorders,
Beckwith-Wiedemann Syndrome (BWS) and Silver-Russell Syndrome (SRS). In contrast to
overgrowth observed for BWS, SRS is characterized by intrauterine growth restriction resulting
in small for gestational age (SGA) births. Other symptoms of SRS vary widely among patients
and include hemihypotrophy, cognitive impairment, macrocephaly, and fifth-finger clinodactyly
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(Wakeling et al., 2017b). Approximately 50% of patients with SRS exhibit IC1 hypomethylation
(Eggermann, Buiting and Temple, 2011). Lack of methylation may allow the formation of an
ectopic insulator on paternal IC1, which likely explains why this class of SRS individuals has
biallelic H19 expression and greatly diminished IGF2 expression (Gicquel et al., 2005; Abi
Habib et al., 2017). Importantly, ICR mutations in the mouse that were generated to study
imprinted gene regulation provided critical information suggesting a role for H19 and IGF2 in
BWS and SRS. For example, mutating CpGs at CTCF sites on the paternal H19/Igf2 ICR resulted
in the loss of ICR methylation, activation of the paternal H19 and reduced Igf2 expression (Engel
et al., 2004). This led to restricted embryonic growth, which is analogous to SRS phenotype.
Nevertheless, although we and others successfully modeled a subset of BWS and SRS mutations
in the mouse, not all mutations were translatable because the mouse H19/Igf2 ICR lacks extensive
sequence conservation with human IC1. Thus, a mouse model with human IC1 sequence
substituted for the endogenous mouse H19/Igf2 ICR was generated (hIC1; Hur et al., 2016) to
model human mutations more precisely. Consistent with expectations, maternally transmitted
hIC1 successfully maintained insulator function, suggesting the possibility to model human IC1
mutations endogenously in mice upon maternal transmission. In contrast, paternally transmitted
hIC1 showed loss of methylation and formation of an ectopic insulator. As a consequence,
paternal hIC1 transmission caused elevated H19 expression and Igf2 depletion together with
growth restriction and perinatal lethality. Although the epigenetic defects and growth restriction
model SRS, in humans, however, the epigenetic defects are mosaic, with certain cell populations
showing normal methylation patterns. Thus, SRS individuals are viable.

The mechanism by which dysregulation of H19/IGF2 expression leads to SRS
phenotypes is unknown, largely because the function of these two genes during development is
incompletely understood. IGF2 is a well-described growth factor promoting fetoplacental growth,
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which functions in an endocrine/paracrine manner through binding to IGF/Insulin receptors
(Harris and Westwood, 2012). Decreased IGF2 levels in patients with SRS suggest that IGF2
contributes to the restricted growth in these patients (Gicquel et al., 2005; Begemann et al., 2015;
Abi Habib et al., 2017). Consistently, in mice, paternal-specific deletion of Igf2 resulted in loss of
Igf2 expression and pre- and postnatal growth restriction (DeChiara, Robertson and Efstratiadis,
1991; Haley et al., 2012). In contrast, the exact role of H19 remains unclear. Previous studies
using mouse models suggested that H19 lncRNA is a precursor for microRNA (miR)-675 that
regulates Igf1r expression (Keniry et al., 2012), and that H19 represses Igf2 expression in trans
(Gabory et al., 2009). As a result, H19 has been largely overlooked and suggested to be an
occasional regulator of Igf2 expression. However, a previously described mouse model with H19
overexpression without changes in Igf2 expression showed embryonic growth restriction (Drewell
et al., 2000), suggesting that H19 has a role as a growth suppressor independent from Igf2. The
hIC1 mouse model therefore provides an opportunity to study the function of these two genes
developmentally and how their dysregulation contributes to SRS phenotypes. In this study, we
utilized three mouse models with various levels of H19 and Igf2 expression to examine the role of
excess H19 in perinatal lethality and pathological defects associated with paternal hIC1
transmission. We report severe developmental defects of major organs such as the heart and
placenta in mice with dysregulated H19/Igf2 expression. Embryos with the paternal hIC1 showed
atrioventricular (AV) cushion defects in the heart, which progress to a ventricular septal defect
(VSD) in later stages, together with extremely thinned myocardial walls. Combined with
placental anomalies, the cardiac defects are most likely to contribute to the lethality of these mice
(Kochilas et al., 1999; Snider and Conway, 2011). Normalization of H19 rescued neither the
lethality nor growth restriction, although we observed a minimal rescue of the earlier growth and
resorption rate. Ultimately, modifying both H19 and Igf2 expression was necessary to rescue the
lethality and the growth restriction, although certain cardiac defects were retained when H19 and
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Igf2 expression were not completely restored to the wild-type level. This work emphasizes the
importance of accurate dosage of H19 and Igf2 expression in normal cardiac and placental
development, of which disruption can lead to SRS-like pathologies.

3.2. Results
Three mouse models with genetic modifications that perturb H19 and Igf2 to different
extents were used to address the phenotypic consequences of abnormal H19 and Igf2 levels
(Figure 3.1B). hIC1 refers to the humanized allele that substitutes the endogenous mouse
H19/Igf2 ICR with the corresponding human sequences, which was initially generated to study
human BWS and SRS mutations in the mouse (Hur et al., 2016; Freschi et al., 2018). Paternal
transmission of hIC1 [+/hIC1] was previously reported to increase H19 and greatly diminish Igf2
expression and resulted in perinatal lethality. A newly derived line, △H19, deletes the H19
transcription unit (Supplemental Figure 3.1). Because H19 is maternally expressed, mice with
maternal transmission of △H19 [△H19/+] are deficient for H19. Finally, we used the previously
described △3.8 allele, which carries a deletion of the H19/Igf2 ICR (Thorvaldsen et al., 2002,
2006). Because of the absence of an insulator, maternal transmission of △3.8 [△3.8/+] activated
the maternal Igf2 allele and diminished H19 expression.

3.2.1. Cardiac and placental defects in +/hIC1 embryos
As previously reported (Hur et al., 2016), +/hIC1 embryos showed severe growth
restriction (Figure 3.2A). The growth restriction appeared as early as E12.5 and was greatly
exaggerated by the end of gestation. At E18.5, +/hIC1 embryos weighed approximately 40% of
their wild-type littermates. +/hIC1 neonates were perinatally lethal, with no live pups found on
the day of birth. The perinatal lethality was observed in both C57BL/6J and 129/S1 strains, thus
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confirming that the lethality is not strain-dependent, in contrast to the previously reported Igf2
knockout mice (Haley et al., 2012). Offspring from this cross were extensively characterized to
ascertain the source of lethality. Lungs collected from dead +/hIC1 neonates floated in water,
demonstrating that +/hIC1 pups respired after birth (Borensztein et al., 2012). Although +/hIC1
neonates did not have a cleft palate, no milk spots were found, indicating a lack of feeding.
Histological analyses were performed throughout development on major organs where H19 and
Igf2 are highly expressed. In contrast to the liver where the paternal hIC1 did not lead to
significant abnormal morphologies (data not shown), severe developmental defects were found in
the +/hIC1 heart and placenta. Cardiac defects in +/hIC1 embryos were observed as early as
E12.5, where the AV cushions were not fused properly (Figure 3.2B). The cushion defect
prompted incomplete interventricular septum (IVS) formation. At E15.5, a severe
perimembranous ventricular septal defect (VSD) was observed in all evaluated +/hIC1 hearts
(Figure 3.2B). Importantly, this congenital heart defect resembles malformations reported in
several SRS patients with IC1 hypomethylation (Ghanim et al., 2013), although the prevalence is
unclear. Additionally, E15.5 hearts showed extremely thin myocardium (Figure 3.2B). Both VSD
and thinned ventricular walls persisted in E17.5 +/hIC1 hearts (Figure 3.2B, C). Additionally, 6
out of 16 +/hIC1 hearts in the late gestation group (E15.5 to P0) had bicuspid pulmonary valve
(BPV), a rare cardiac defect in which the pulmonary valve has only two cusps as opposed to the
normal tricuspid structure (Figure 3.2D). These results demonstrate that paternal hIC1
transmission results in variably penetrant cardiac phenotypes. As the heart is critical in supplying
oxygen and nutrients for the rest of the developing body, the cardiac defect likely contributed
substantially to fetal growth restriction (Savolainen, Foley and Elmore, 2009; Spicer et al., 2014).
Moreover, the severity of the defects shown in +/hIC1 hearts likely lead to a reduction in cardiac
function that could be responsible for the observed perinatal lethality.
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Another major organ with high H19/Igf2 expression, which forms early in development is
the placenta. Multiple developmental defects were observed in +/hIC1 placentas. As previously
described (Hur et al., 2016), +/hIC1 placentas were growth restricted throughout development
(Figure 3.3A). The fetus to placenta weight ratio was lower in +/hIC1 conceptuses, indicating
that the fetal growth restriction was more severe than the placental growth restriction (Figure
3.3B). In addition to placental undergrowth, the junctional to labyrinth zone ratio was increased
in +/hIC1 placentas (Figure 3.3C), suggesting that the growth of the labyrinth, where the
maternal-fetal exchange occurs, was more affected. H19 overexpression was exaggerated in the
labyrinth in +/hIC1 placentas, while the Igf2 depletion was consistent throughout the whole
placenta (Figure 3.3D), indicating that H19 overexpression contributed disproportionately to the
phenotype of growth restriction in the labyrinth. At E17.5, large thrombi were observed in the
labyrinth zone of the +/hIC1 placentas (Figure 3.3F), in a male-skewed manner (Figure 3.3E). As
the thrombi could be formed due to defective vasculature structures, wild-type and +/hIC1
placentas were stained for CD34, a marker for the fetoplacental endothelial cells that line the
microvessels in the labyrinth layer (Figure 3.3G). Vessels in the +/hIC1 labyrinth were highly
dilated and had decreased density, which was confirmed by quantifying the stained areas on the
images (Figure 3.3H). The reduced labyrinth layer and defective vasculature structures likely
compromised the ability of +/hIC1 placentas to supply nutrients and oxygen for the fetus. These
results support that the abnormal growth of +/hIC1 embryos may be explained by failure in
multiple organs, especially the heart and placenta, which are developmentally linked.

3.2.2. Normalizing H19 expression partially rescues paternal hIC1 defects
It has been previously reported that Igf2 null mice are viable (DeChiara, Robertson and
Efstratiadis, 1991). Thus, we hypothesize that H19 overexpression combined with a loss of Igf2
expression is the molecular contributor to the lethality of paternal hIC1 transmission. To examine
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if reduced H19 expression would rescue the paternal hIC1 transmission phenotypes, a mouse
model with deletion of the H19 transcription unit [△H19] was generated (Supplemental Figure
3.1A and B). Consistent with previous reports, maternal deletion of H19 [△H19/+] led to a lack
of H19 expression and tissue-specific minimal activation of maternal Igf2 (Supplemental Figure
3.1C). These mice are viable and fertile, regardless of whether the deletion is maternally or
paternally transmitted, although maternal transmission is associated with increased fetal weight
from E14.5 and onwards (Supplemental Figure 3.1D and data not shown).

Heterozygous △H19 females were mated with heterozygous hIC1 males to generate

△H19/hIC1 embryos. These embryos were expected to have lower H19 expression compared to
+/hIC1 embryos, as the maternal H19 expression was silenced (Figure 3.4A). Among four
possible genotypes from this breeding, +/hIC1 embryos constituted approximately 15% per litter
at E17.5, as opposed to the expected Mendelian ratio of 25%. In contrast, △H19/hIC1 embryos
comprised approximately 30% per litter at E17.5, indicating partial rescue of the resorption rate
by maternal H19 deletion (Figure 3.4B). However, △H19/hIC1 embryos still exhibited perinatal
lethality, with no live pups observed. With respect to growth restriction, the maternal △H19 allele
only partially rescued the phenotype. At E11.5, △H19/hIC1 fetal weight was not significantly
different from wild-type littermates (Figure 3.4C). However, late in gestation (E17.5), although

△H19/hIC1 fetuses had a significant increase in fetal weight compared to the +/hIC1 fetuses,
△H19/hIC1 fetuses remained significantly smaller compared to wild-type. As perinatal lethality
was still observed, conceptuses were analyzed histologically to characterize their developmental
defects. The AV cushion defect persisted in E13.5 △H19/hIC1 embryos and both
perimembranous and muscular VSDs were observed at E17.5 (Figure 3.4D). Thrombi were still
present in around 50% of △H19/hIC1 placentas (Figure 3.4E), and placental weight also
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remained significantly lower than wild-type littermates (Supplemental Figure 3.2A). Of note,
none of these histological defects were observed in △H19/+ embryonic hearts and placentas
(Figure 3.4D and data not shown). E17.5 △H19/hIC1 tissues demonstrated wild-type levels of
H19 expression, while the Igf2 expression remained severely lower than the wild-type (Figure
3.4F and Supplemental Figure 3.2B). From these results, we conclude that restoring only H19
expression is not sufficient to rescue completely the lethality and developmental defects upon
paternal transmission of hIC1. Thus, phenotypes are likely caused by abnormal expression of
both H19 and Igf2.

3.2.3. Paternal hIC1 defects are rescued by deletion of the maternal H19/Igf2 ICR
A previously published mouse model with a 3.8-kb deletion spanning the H19/Igf2 ICR
[△3.8] was utilized to modify both H19 and Igf2 expression (Thorvaldsen et al., 2002, 2006).
Because the absence of the maternal H19/Igf2 ICR allows the interaction between the Igf2
promoter and the downstream enhancer. Igf2 expression from the maternal allele in △3.8/hIC1
embryos is expected to restore Igf2 levels (Figure 3.5A).

Crosses between heterozygous △3.8 females and heterozygous hIC1 males produced the
expected mendelian ratio of offspring with △3.8/hIC1 mice appearing fully viable. Both fetal and
placental weights were not significantly different between △3.8/hIC1 and wild-type at E17.5
(Figure 3.5B and Supplemental Figure 3.3A), demonstrating full rescue of both the lethality and
the growth restriction. However, VSDs were observed in both △3.8/+ and △3.8/hIC1 embryonic
hearts (Figure 3.5C) at E15.5 and E17.5, although the lesions in the IVS were smaller than those
found in +/hIC1 hearts. Igf2 expression in the E17.5 △3.8/hIC1 hearts was restored to wild-type
levels. However, normalization of H19 expression was variable among embryos. Although not
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statistically significant in heart, △3.8/hIC1 embryos showed trends of higher H19 expression
compared to the wild-type littermantes (Figure 3.5D and Supplemental Figure 3.3B). These
results suggest that the physiological levels of H19 and Igf2 expression are critical for normal
cardiac development. No thrombi were detected in the △3.8/hIC1 placentas, and the placental
morphology was normal with the junctional to labyrinth zone ratio not significantly different
from that of wild-type (Supplemental Figure 3.3C). In sum, restoring both H19 and Igf2 to near
wild-type levels was necessary for the full rescue of the most severe pathologies of paternal hIC1
transmission.

3.3. Discussion
In this study, we showed that the overexpression of H19 combined with Igf2 depletion
leads to severe morphological defects in the heart and placenta. These cardiac and placental
defects are likely to be highly correlated with the perinatal lethality and restricted growth
observed in +/hIC1 embryos. To examine if increased H19 is causing the malformation of the
two organs, we evaluated cardiac and placental morphologies of mouse models with various
levels of H19 and Igf2 expression. Genetically correcting H19 was not sufficient for the full
rescue of the developmental defects, which indicated that the SRS-like phenotypes of paternal
hIC1 transmission are not solely attributable to H19 overexpression. Unexpectedly, although
moderately adjusting both H19 and Igf2 rescued the lethality, septal defects persisted in these
embryos (△3.8/hIC1). This demonstrates that cardiac development is extremely sensitive to the
accurate dosage of H19 and Igf2.

In mice, ventricular septation is completed around E13.5 to E14 (Savolainen, Foley and
Elmore, 2009), when both H19 and Igf2 are highly expressed in the cardiac endocardium and
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epicardium (Shen et al., 2015; García-Padilla et al., 2019). The fusion of AV cushions and
ventricular septation, both of which require a fine-tuned regulation of endothelial-mesenchymal
transition (EMT) (Von Gise and Pu, 2012), was disrupted by paternal hIC1 transmission. Thus,
the role of H19 and Igf2 in endocardial EMT during development warrants further examination.
Previous studies reported that H19 regulates EMT and cell proliferation in cancer models
(Matouk et al., 2016; Shermane Lim et al., 2021). A recent study showed that H19 promotes
EMT in human aortic endothelial cells in vitro and mouse microvascular endothelial cells in vivo
(Cao et al., 2020). H19, which is significantly increased in failing adult murine hearts (Lee et al.,
2011), has been associated with cardiac remodeling after ischemic heart failure (Greco et al.,
2016; Hobuß et al., 2020) and was suggested to repress cardiomyocyte growth (Liu et al., 2016).
However, the function of H19 in cardiac development has not drawn much attention. H19 is
highly expressed in the developing heart, especially in the cardiac endocardium (García-Padilla et
al., 2019). It is worth noting that the localization of endocardial H19 is nuclear early in gestation
and becomes cytoplasmic in neonates. H19 is also localized to the nucleus of the endocardial
lining, while showing cytoplasmic localization in the mesenchymal component (García-Padilla et
al., 2019). Both the temporal and spatial changes coincide with cardiovascular EMT, suggesting
that H19 is crucial to the transcriptional regulation of endocardial EMT in early development.

In contrast to the less well understood role for H19, Igf2 is the main growth factor in the
developing ventricular wall. Deleting Igf2 and its receptors caused decreased cardiomyocyte
proliferation and ventricular hypoplasia, indicating that Igf2 is the major regulator of ventricular
wall thickening (Li et al., 2011; Shen et al., 2015). However, the thinned myocardium found in
Igf2 knockout mouse embryos was resolved at the time of birth, resulting in neonatal hearts with
normal cardiac morphology (Shen et al., 2020). In contrast to the Igf2-knockout mouse, cardiac
defects (thinned myocardium and septal defects) of +/hIC1 and △H19/hIC1 embryos were
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aggravated towards the end of gestation, indicating that these phenotypes are not exclusively
attributable to the loss of Igf2 expression. We conclude that Igf2 deficiency in +/hIC1 hearts is
the major cause of the ventricular wall thinning as the recovery of Igf2 expression in △3.8/hIC1
hearts leads to the rescue from ventricular hypoplasia. This is in line with previous findings (Li et
al., 2011; Shen et al., 2015). However, septal defects persist in △3.8/+ and △3.8/hIC1 embryos,
both of which did not exhibit ventricular hypoplasia. Although we and others showed that
restoring Igf2 successfully rescues the growth restriction in SRS-like mouse models (Han, Szabó
and Mann, 2010; Liao et al., 2021), septal defects under Igf2 dysregulation were not yet reported.

IVS consists of both mesenchymal and muscular components (Penny and Vick, 2011;
Spicer et al., 2014). Therefore, reduction in cardiomyocyte proliferation can also lead to VSD
(Snider and Conway, 2011). This suggests that the lack of Igf2, a growth promoter for
cardiomyocytes, contributes to the septal defects observed in +/hIC1 and △H19/hIC1 hearts. Our
data provide evidence that the ventricular septation may be regulated separately from the
ventricular wall thickening, and that both events are extremely sensitive to the level of H19 and
Igf2 expression. In humans, VSDs were found in patients with IC1 hypomethylation (Ghanim et
al., 2013) and a patient carrying chromosomal gain of chr11p15 (Serra et al., 2012), supporting
that abnormal H19 and IGF2 expression could disturb the proper regulation of ventricular
septation in humans. To further understand the role of H19 and Igf2 in developing endocardium
and IVS, we are currently investigating the transcriptomic profiles of CD31+ cardiac endothelial
cells of mouse models utilized in this study.

Linked through fetoplacental blood circulation, the heart and placenta are closely
connected during development (Barak, Hemberger and Sucov, 2019). The development of both
organs begins early in gestation and both are responsible for supplying nutrients and oxygen for
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developing fetuses. Placental defects are often coupled with cardiac defects in subviable or lethal
mouse mutants (Perez-Garcia et al., 2018). In humans, lower placental weights show positive
correlations with an incidence of congenital heart defects (CHDs) (Matthiesen et al., 2016;
Rychik et al., 2018). It has only been recently appreciated that the cardiac and placental
developments are tightly co-regulated under the cardiac-placental axis, which is crucial for fetal
growth and viability (Maslen, 2018). Igf2 mediates the interaction between the heart and placenta,
as epicardial Igf2 expression in developing ventricles is induced by a normoxic environment that
is dependent on the placental function (Shen et al., 2015). In contrast, H19 is upregulated under
hypoxic conditions in mouse cardiomyocytes (Choong et al., 2019) and in human endothelial
cells in vitro (Dico et al., 2016). Hypoxia can also disrupt cardiac morphogenesis, leading to
severe defects emerging especially in cushions and septa (Dor et al., 2001). Together, this
suggests that placental maintenance of a normoxic fetal environment is vital for cardiac
development, and H19 and Igf2 are important mediators of this interaction. As the heart and
placenta are responsible for meeting the fetal demand for nutrients and oxygen, the malfunction
of these two organs would severely constrain embryonic growth. Therefore, the precise role of
H19 and Igf2 in cardiac-placental communication needs to be clarified to understand how the
SRS-related growth restriction is induced by IC1 hypomethylation.

The labyrinth, where +/hIC1 placentas show abnormal vasculature morphology and
thrombosis, serves as a prime location for maternal-fetal blood exchange (Woods, Perez-Garcia
and Hemberger, 2018). Placental thrombosis can be caused by defective labyrinth integrity and
has been associated with restricted fetal growth. Diminished labyrinth function could limit the
nutritional and oxygen supply for a fetus, which can, in turn, lead to hypoxia and growth
restriction. There are many evidences that support the roles for H19 and Igf2 in placental
development as both are highly expressed in fetoplacental endothelial cells (FPECs) that line the
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fetal capillaries in the labyrinth zone (Aykroyd, Tunster and Sferruzzi-Perri, 2021; Sandovici et
al., 2021). Proliferation of FPECs is important for normal placental angiogenesis, and genetically
depleting Igf2 expression in FPEC disrupted the remodeling of fetal capillaries and led to
decreased labyrinth size (Sandovici et al., 2021). Consistently, deleting Igf2 in the epiblast
lineage caused the formation of thrombi in the labyrinth, although the lesions were smaller in size
than those observed in +/hIC1 placentas (Sandovici et al., 2021). Depletion of placental-specific
Igf2 transcript in mice resulted in smaller labyrinth, severely decreased diffusional capacity of the
placenta, and fetal growth restriction (Constância et al., 2002; Sibley et al., 2004). However,
these mice showed an increased fetus to placental weight ratio, which was decreased in +/hIC1
mice. This contrasting result could be explained by the effect of the increased H19 expression in
+/hIC1 mice. H19 overexpression induced production and secretion of vascular endothelial
growth factor (VEGF) in human endothelial cells in vitro (Conigliaro et al., 2015), which is
involved in placental angiogenesis, specifically for the branching of fetoplacental vessels
beginning at mid-gestation (Woods, Perez-Garcia and Hemberger, 2018). Additionally, H19
expression is very high in trophoblasts (Poirier et al., 1991; Marsh and Blelloch, 2020). It has
been previously reported that the disrupted development of trophoblastic cells in the labyrinth
leads to defective vascular branching in the labyrinth and restricted fetal growth (Ueno et al.,
2013). Thus, it is possible that the morphological anomalies observed in the +/hIC1 placenta are
exaggerated by abnormal H19 expression in trophoblasts. As the placenta is immediately
separated from the fetus at birth, placental defects are often dismissed as a potential cause for
postnatal defects. However, others have reported incidence of a perinatally lethal mouse model
showing no other morphological defects besides severe thrombi formed in the placenta (Castillo
et al., 2020). This supports our posit that fetal damage from defective placental function can
persist beyond the gestational period. Thus, examining placental morphology may be useful to
quickly diagnose and anticipate progressive defects in patients born with congenital anomalies.
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Many patients with SRS exhibit epigenetic defects in a mosaic manner, with the
distribution (i.e. the affected cell types) of the epimutation being critical in the severity of patient
symptoms. Depending on the distribution of epimutation, even monozygotic twins can be affected
differently with SRS features (Gicquel et al., 2005). While most individuals with SRS are viable,
there was a report of SRS patients with IC1 hypomethylation who died shortly after birth and had
unusual CHDs (Ghanim et al., 2013). This suggests that certain organs are more vulnerable to
dysregulated H19/IGF2 expression and are more critical to the patient’s survival. Thus, although
widely expressed, H19 and IGF2 might have more important roles in certain organs. CHDs,
including VSD, have been reported in SRS individuals with IC1 hypomethylation (Ghanim et al.,
2013). VSD is one of the most common congenital cardiac malformations (Spicer et al., 2014)
and can lead to double outlet right ventricle (DORV) (Mostefa-Kara, Houyel and Bonnet, 2018),
which has been previously reported in SRS patients. Thus, the VSD observed in our mouse model
with the paternal hIC1 transmission nicely models the SRS-associated CHD in human patients. It
should be noted, however, that mice are often more susceptible to VSDs than humans. Mice with
VSDs show a higher neonatal mortality rate, possibly due to the higher heart rates and relatively
larger size of VSD lesions (Snider and Conway, 2011). Additionally, cardiac defects that are
lethal in mice can lead to spontaneous miscarriages in humans because the human gestation
period is much longer, making it difficult to observe human infants with similar defects.

In summary, we provide evidence that the proper dosage of H19 and Igf2 is essential for
normal cardiac and placental development. Investigation of the role of H19 and Igf2 in the
cardiac-placental axis will enable a better understanding of how paternal hIC1 transmission leads
to the SRS-like growth restriction and perinatal lethality. This work provides insight into how the
severity of SRS phenotypes varies among patients. Ultimately, we hope that identifying organs
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that are extremely sensitive to H19 and Igf2 dysregulation will enable us to identify key signaling
pathways that could be targeted for early intervention of SRS-associated pathologies.

3.4. Contributions
Suhee Chang designed the study, characterized and maintained hIC1, △H19 and △3.8
mouse models, performed allele-specific and total expression analyses, performed dissections and
collected mouse tissue samples, recorded the weight and genotype ratio data, prepared embryonic
heart samples for histological analyses, prepared, stained and analyzed placental sections, and
wrote the manuscript. Stella Hur generated the △H19 mouse model. Joanne Thorvaldsen
maintained hIC1 and △3.8 mouse models, characterized the △H19 mouse model and edited the
manuscript. Diana Fulmer performed cardiac histological analyses. Lisa Vrooman and Eric Rhon
evaluated placental sections. Kashviya Suri measured the ventricular wall thickness. Marisa S.
Bartolomei designed the study, analyzed experiments, and wrote the manuscript.
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Figure 3.1. H19/IGF2 cluster and mouse models utilized in this study.
(A) A schematic representation of the wild-type H19/Igf2 cluster. The maternally-expressed H19
is shown in red and the paternally-expressed Igf2 are shown in blue. Black lollipops on the
paternal allele represent DNA methylation. The maternal ICR is bound to CTCF proteins (pink
hexagons), forming an insulator to block the maternal Igf2 promoter from the downstream shared
enhancers (green circles). Therefore, the enhancer interacts with the H19 promoter on the
maternal allele, and Igf2 is expressed from the paternal allele. Gray lines on the ICR represent
conserved CTCF binding sequences. (B) Schematics of the mouse endogenous H19/Igf2 ICR,
hIC1 (Hur et al., 2016), △H19, and △3.8 (Thorvaldsen et al., 2002, 2006) alleles.
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Figure 3.2. Growth anomalies and cardiac defects of +/hIC1 embryos.
(A) Fetal weight of the wild-type (blue) and +/hIC1 (red) embryos at E11.5, E14.5, E17.5 and
E18.5. Each data point represents an average weight of each genotype from one litter. (B)
Representative cross-sections of the wild-type and +/hIC1 embryonic hearts at E12.5, E15.5 and
E17.5, stained with hematoxylin and eosin. Note the lack of fusion between AV cushions at
E12.5, the VSD at E15.5 and E17.5 in +/hIC1 hearts (yellow arrowheads). The boxed regions of
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E15.5 and E17.5 images are enlarged at the bottom of the figure, to show where the ventricular
wall thickness is measured. Scale bars = 500 µm. (C) Quantification of ventricular wall thickness
(µm), measured from E17.5 wild-type and +/hIC1 hearts. Each data point represents individual
conceptus from four different litters. (D) A representative image of pulmonary valves in the
E17.5 wild-type and +/hIC1 hearts. Note that the +/hIC1 pulmonary valve shows a bicuspid
structure (yellow arrowhead), in contrast to the tricuspid structure in the wild-type heart. Scale
bars = 500 µm. (A) Multiple paired t-test, (C) Multiple unpaired t-test; **P < 0.01, ****P <
0.0001, ns = not significant.
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Figure 3.3. Placental defects of +/hIC1 embryos.
(A) Placental weight of the wild-type (blue) and +/hIC1 (red) samples at E11.5, E14.5, E17.5 and
E18.5. Each data point represents an average weight of each genotype from one litter. (B) Fetal to
placental weight ratios in E17.5 wild-type and +/hIC1 samples (mean ± SD). (C) Junctional zone
(Jz) to labyrinth (Lb) ratio in E17.5 wild-type and +/hIC1 placentas. (D) Relative total expression
of H19 and Igf2 in E17.5 wild-type and +/hIC1 placentas and labyrinths (mean ± SD). (E)
Number of the wild-type, male and female +/hIC1 placentas with thrombi observed. (F)
Representative cross-sections of E12.5, E15.5 and E17.5 wild-type and +/hIC1 placentas stained
with hematoxylin and eosin. Black arrowhead indicates a large thrombus formed in the +/hIC1
labyrinth. Scale bars = 1mm. (G) Representative images of CD34 immunostaining counterstained
with hematoxylin on E17.5 wild-type and +/hIC1 placental sections. Black arrowheads indicate
thrombi in the +/hIC1 labyrinth. Scale bars = 1mm. (H) Quantification of the microvessel density
in E17.5 wild-type and +/hIC1 placentas.
(B, C, D, H) Each data point represents an individual conceptus from different litters. (A)
Multiple paired t-test, (B) Unpaired Student’s t-test, (C, D, H) One-way ANOVA with Tukey’s
multiple comparisons test, (E) Fisher’s exact test; *P < 0.05, **P < 0.01, ***P < 0.001, ****P <
0.0001, ns = not significant.
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Figure 3.4. Normalizing H19 expression through the maternal deletion of H19.
(A) A schematic representation of the rescue breeding between △H19 heterozygous female and
hIC1/+ male mice. △H19/hIC1 embryos are expected to express H19 only from the paternal
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allele. (B) Ratio of +/hIC1 and △H19/hIC1 embryos observed in E11.5 and E17.5 litters (>5
pups). Each data point represents one litter. (C) Relative fetal weights of wild-type, △H19/+,
+/hIC1 and △H19/hIC1 embryos at E11.5 and E17.5, normalized to the average body weight of
the wild-type littermates (mean ± SD). (D) Representative cross-sections of wild-type, △H19/+
and △H19/hIC1 embryonic hearts at E13.5 and E17.5, stained with hematoxylin and eosin. Note
the cushion defect at E13.5 and the VSD at E17.5 in △H19/hIC1 hearts (yellow arrows). Scale
bars = 500 µm. (E) (Top) Representative cross-sections of E17.5 △H19/hIC1 placenta stained
with hematoxylin and eosin. Black arrowhead indicates a thrombus. Scale bar = 1mm. (Bottom)
Number of the wild-type, male and female +/hIC1 placentas with thrombi observed. (F) Relative
total expression of H19 and Igf2 in E17.5 wild-type, △H19/+, +/hIC1 and △H19/hIC1 hearts
(mean ± SD). (C, F) Each data point represents an individual conceptus from different litters. (B,
C, F) One-way ANOVA with Tukey’s multiple comparisons test, (E) Fisher’s exact test; *P <
0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, ns = not significant.
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Figure 3.5. Restoring H19 and Igf2 expression utilizing maternal H19/Igf2 ICR deletion.
(A) Schematic representation of the rescue breeding between △3.8 heterozygous female and
hIC1/+ male mice. △3.8/hIC1 embryos are expected to show activation of maternal Igf2
expression as well as paternal H19 expression. (B) Relative fetal weights of wild-type, △3.8/+,
+/hIC1, and △3.8/hIC1 embryos at E11.5 and E17.5, normalized to the average body weight of
wild-type littermates (mean ± SD). (C) Representative cross-sections of wild-type, △3.8/+ and

△3.8/hIC1 embryonic hearts at E15.5 and E17.5, stained with hematoxylin and eosin. Note the
VSD in △3.8/+ and △3.8/hIC1 hearts (yellow arrows). Scale bars = 500 µm. (D) Relative total
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expression of H19 and Igf2 in E17.5 wild-type, △3.8/+, +/hIC1, and △3.8/hIC1 hearts (mean ±
SD). (B, D) Each data point represents an individual conceptus from different litters. One-way
ANOVA with Tukey’s multiple comparisons test; *P < 0.05, ***P < 0.001, ****P < 0.0001, ns
= not significant.

78

Supplemental Figure 3.1. Characterization of △H19 allele.
(A) Targeting strategy to generate the △H19 allele. Endogenous H19 locus is shown with
restriction sites, gRNA sites and binding sites for probes used in Southern blot analysis (thick
lines). (B) Southern blot analysis of △H19 allele. Founder 4131 line was generated using gRNA
pair A, and founder 4133 line was generated using gRNA pair B (details in chapter 5.13). 3’
probe and 5’ probe were hybridized to XbaI- and KpnI-digested DNA, respectively. The sizes of
the DNA fragments are shown on the right. (C) Allele-specific Igf2 expression in wild-type and

△H19/+ neonate tongue, heart and liver analyzed by restriction fragment length polymorphism
(RFLP). Ladder, genotypes and Cast (maternal) and BL6 (paternal) allele controls are indicated
above each gel. Quantification of band densitometry is shown below each gel. (D) Neonatal body
weight of △H19/+ and +/△H19 pups (mean ± SD). Unpaired Student’s t-test; ****P < 0.0001,
n.s. = not significant.
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Supplemental Figure 3.2. Supplementary data for rescue with maternal △H19 transmission.
(A) Relative placental weights of E17.5 wild-type, △H19/+, +/hIC1 and △H19/hIC1 samples,
normalized to the average placental weight of the wild-type littermates (mean ± SD). (B) Relative
total expression of H19 and Igf2 in E17.5 wild-type, △H19/+, +/hIC1 and △H19/hIC1 liver and
tongue samples (mean ± SD). (A, B) Each data point represents an individual conceptus from
different litters. One-way ANOVA with Tukey’s multiple comparisons test; *P < 0.05, **P <
0.01, ***P < 0.001, ****P < 0.0001, ns = not significant.
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Supplemental Figure 3.3. Supplementary data for rescue with maternal △3.8 transmission.
(A) Relative placental weights of E17.5 wild-type, △3.8/+, +/hIC1 and △3.8/hIC1 samples,
normalized to the average placental weight of the wild-type littermates (mean ± SD). (B) Relative
total expression of H19 and Igf2 in E17.5 wild-type, △3.8/+, +/hIC1 and △3.8/hIC1 liver and
tongue samples (mean ± SD). (C) Jz to Lb ratio in E17.5 wild-type, △3.8/+, +/hIC1 and

△3.8/hIC1 placentas. (A, B, C) Each data point represents an individual conceptus from different
litters. One-way ANOVA with Tukey’s multiple comparisons test; *P < 0.05, **P < 0.01, ***P <
0.001, ****P < 0.0001, ns = not significant.
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CHAPTER 4. FUTURE DIRECTIONS
4.1. A BWS model utilizing human induced pluripotent stem cells (hiPSCs)
Cardiac differentiation of hiPSC clones
In chapter 3, we showed that H19 and Igf2 are important regulators of cardiac
development. CHDs, including VSD, are reported in up to 20% of patients with BWS, and
clinical cardiovascular examination is strongly recommended for all children diagnosed with
BWS (Brioude et al., 2018). Additionally, a VSD was found in a patient with a chromosomal gain
of chr11p15 spanning through H19/IGF2 locus, showing the correlation between the BWSassociated H19/IGF2 dysregulation and a cardiac malformation (Serra et al., 2012). Thus, it is
necessary to clarify how cardiac development is affected by abnormal H19/IGF2 expression in
the presence of BWS mutations, including pUPD11. Importantly, previous studies demonstrated
that hiPSCs could be successfully differentiated into cardiomyocytes (Lian et al., 2012, 2013;
Feyen et al., 2020). Additionally, we have shown that our iPSC clones could maintain the
expected imprinting status of the pUPD11-relevant ICRs throughout hepatic differentiation, with
pUPD11 clones expressing increased IGF2 and decreased H19. Considering that Igf2 is the main
growth promoter for cardiomyocytes during development in mice (Li et al., 2011), it is
reasonable to hypothesize that increased IGF2 expression in pUPD11 clones would affect the
cardiogenic differentiation process. Thus, by comparing the differentiated pUPD11 and nonpUPD11 cardiomyocytes, we could examine how the H19/IGF2 dysregulation due to pUPD11
can lead to cardiac defects observed in BWS patients.

Comparison with human samples
In order to evaluate our hiPSC model as a tool for human BWS research, it is essential to
compare our hiPSC-derived hepatocytes to the human tissue collected. Our collaborators are
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currently screening transcriptomes of hepatoblastoma tissues collected from patients with and
without BWS. It would be interesting to examine if the transcriptomic profile of our pUPD11
hepatocytes has any overlap with those of human hepatic tissues with BWS. However, it should
be noted that the pUPD11 might not be present in BWS patients from whom the hepatoblastoma
samples are collected. Moreover, considering that the molecular subtype of BWS largely affects
the phenotype, it may not be an appropriate comparison if the molecular lesions are not matched
between the patient sample and hiPSC-derived hepatocytes. Additionally, it would be difficult to
interpret the difference between the homogeneous pUPD11 hepatocytes and the mosaic pattern
observed in patient tissues. The best solution would be to generate new iPSC clones and perform
hepatic differentiation using skin fibroblasts of the patient from whom the hepatic tissue was
collected. Furthermore, our collaborators have access to tongue samples that were collected
during the glossectomy procedure on patients with BWS. Macroglossia is one of the most
representative symptoms of BWS (Brioude et al., 2018). Comparing the patient tongue samples
into myoblasts differentiated from our hiPSC clones would help us better understand the tongue
muscle-specific overgrowth in BWS.

4.2. Role H19/Igf2 dysregulation in SRS-like mouse model
Identifying the binding partner(s) of H19 lncRNA
Our work described in the previous chapter prompted the hypothesis that the H19
lncRNA regulates endocardial EMT in the developing heart. Although we and others showed that
abnormal H19 expression leads to pathological phenotypes in mice (Chang and Bartolomei,
2020), the exact mechanism of how H19 exerts its function is controversial. Several studies
hypothesize that H19 acts through the microRNA (miR)-675, which is encoded in the first exon
of H19 (Matouk et al., 2016). MiR-675 has been suggested to repress placental growth through
targeting Igf1r (Keniry et al., 2012) although a recent report showed that altered H19 expression
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did not result in a change in the expression of Igf1r and other known targets of miR-675 in the
placenta (Aykroyd, Tunster and Sferruzzi-Perri, 2021). Thus, the true targets of miR-675 or H19
lncRNA, as well as whether miR-675 is essential in mediating H19 function, need to be clarified.
RNA-IP experiments using antibodies for candidate H19-binding proteins were
performed in several studies (Monnier et al., 2013; Zhang et al., 2013). Moreover, chromatin
isolation by RNA purification (ChIRP), a pulldown experiment using H19 probes, has been
designed to find the binding partners of H19 (Chu et al., 2011; Choong et al., 2019). However,
these experiments have not utilized the embryonic tissues where H19 is the most highly
expressed. Thus, there have been limitations in clarifying the downstream regulator(s) interacting
with H19 during development in vivo. A ChIRP assay with H19 probes on embryonic hearts of
mouse models utilized in this study, followed by mass spectrometry analysis, would enable the
identification of the crucial binding partner(s) of H19 in mouse cardiac development.

Tissue-specific hIC1 and rescue
We reported severe morphological defects in the heart and placenta with abnormal
H19/Igf2 expression, which are likely damaging cardiac and placental function and ultimately
contributing to the perinatal lethality. However, in order to determine if these defects are directly
causing death in the +/hIC1 mice, a conditional hIC1 mouse model needs to be generated.
Utilizing cardiac-specific Cre drivers such as Nkx2.5Cre (Moses et al., 2001) would allow the
generation of a mouse model with a heart-specific knock-in of the hIC1 allele. Additionally,
combination with other endothelial-specific Cre models (Payne, Val and Neal, 2018) such as
Tie2Cre (Kisanuki et al., 2001), which is active in endocardial lining and cushions, would clarify
the role of the endocardium in +/hIC1-associated cardiac malformation. The same strategy is
applicable to placentas, as there are placental cell-specific Cre lines available (Wattez et al.,
2019). This would allow us to determine the temporal order of cardiac and placental defects, as
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one may be preceding the other. It would also enable mimicking the mosaicism seen in human
patients with epimutations. Ultimately, the tissue-specific rescue of +/hIC1 phenotype would
conclude if the heart and placenta are truly the most susceptible organs to H19/Igf2 dysregulation
and most critical for the survival of the mice.

H19/Igf2 in cardiac remodeling
As regulators of cardiomyocyte proliferation during development, H19 and Igf2 could be
important in the cardiac remodeling of adult hearts. Previous studies showed that H19 is
upregulated in infarcted murine hearts after ischemic injuries, and H19 has been implicated in the
recovery process from ischemic heart failure (Greco et al., 2016; Hobuß et al., 2020). Although
adult +/hIC1 hearts are not available as +/hIC1 mice are perinatally lethal, △3.8/hIC1 mice,
which still show dysregulated H19/Igf2 expression and congenital cardiac defects, are viable. The
adult △3.8/hIC1 mouse hearts could be utilized to determine the effect of H19/Igf2 dysregulation
on the post-infarction recoveries.

Cause of hypomethylation on the paternal hIC1
How the paternal hIC1 fails to establish and maintain DNA methylation in mice is
unclear. Previously we showed that the hIC1 allele is enriched with H3K4me2, an activating
histone modification, in male germ cells (Hur et al., 2016). We hypothesized that this is
potentially due to the incomplete erasure of histone modifications during male germ cell
reprogramming. As +/hIC1 mice are perinatally lethal, the previously examined hIC1 alleles in
male germ cells were originated from the maternal allele of hIC1/+ somatic cells. Considering
that the maternal hIC1 is hypomethylated and enriched with active histone modifications, the
imperfectly erased histone marks could have interrupted the establishment of paternal-specific
DNA methylation on the hIC1 allele in male germ cells. Because it is equally possible that the
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hypomethylated hIC1 allele belatedly recruited active histone marks, the enrichment of H3K4me2
on the hIC1 allele could be either the cause or the result of the DNA hypomethylation. To
determine if the lack of DNA methylation precedes the enrichment of the histone marks, we are
currently examining the DNA methylation status of the hIC1 allele in male primordial germ cells.
Additionally, the paternal inheritance of the hIC1 allele for more than one generation has
been impossible because +/hIC1 males die at birth and therefore cannot generate offspring.
However, the fully viable and fertile △3.8/hIC1 males enable us to examine if the paternal
inheritance of the hIC1 allele would surpass the imperfect reprogramming of maternal allelespecific histone marks. If so, it may enhance the establishment of DNA methylation on the hIC1
allele of male germ cells. Furthermore, as the TET1 enzyme is responsible for the active
demethylation process during germ cell reprogramming, DNA methylation on the hIC1 allele in
Tet1-null mice might be affected by the lack of active demethylation machinery.
Why the human IC1 sequence fails to hold proper DNA methylation in mice is an
intriguing question. Another possible answer is that human and mouse ICR sequences have
different binding affinities to zinc-finger proteins (ZFPs). A previous report showed that ZFP57
and ZNF445/ZFP445 are utilized to maintain murine and human imprints during development
with different specificity (Takahashi et al., 2019). In early development, the expression of
ZFP445 is lower than ZFP57 in mice, whereas in humans ZFP445 expression is much higher than
ZFP57. It is possible that the low levels of ZFP445 in murine environment could not support the
maintenance of proper imprinting on the hIC1 allele. ZFP445-ChIP-qPCR analysis on hIC1
sequence utilizing +/hIC1 early embryos would determine if the different usage of ZFPs between
human and mouse ICRs causes the hypomethylation on the paternal hIC1 allele.
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4.3. Conclusions
For over 30 years, two imprinted growth regulators, H19 and IGF2, have generated many
intriguing questions about both their regulation and function. Numerous studies proved that H19
and IGF2 are involved in major growth pathways, and their dysregulation leads to various
pathological phenotypes in mice and humans. Nevertheless, it is unsatisfying that patient
symptoms caused by H19/IGF2 dysregulation still have no clinical methods of early intervention.
This may be due to difficulties in translating mouse research to human, or the lack of proper
human genetic models. But mostly, it is attributable to our lack of full and accurate understanding
of the exact role of H19 and IGF2, especially in tissues that are prone to BWS/SRS anomalies.
The studies in this dissertation aimed to clarify H19 and IGF2 function in leading to
developmental defects. The patient cell-derived hiPSC model allowed us to examine the effect of
the BWS mutation without complications of mosaicism, tissue access, or divergent genetic
backgrounds. An SRS-like mouse model with the paternal hIC1 allele taught us that certain
organs are more susceptible to H19/Igf2 dysregulation, and such organs may be more impactful
for patient survival and health. Ultimately, these tools allowed us to clarify the downstream
pathways of H19 and IGF2, which would help to establish therapeutic approaches to prevent
pathological defects caused by H19/IGF2 dysregulation in the future.
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CHAPTER 5. MATERIALS AND METHODS
5.1. Patient clinical features and genetic testing
Clinical information, clinical testing results, and fibroblast samples were collected from
the Children’s Hospital of Philadelphia BWS registry/repository (IRB #13-010658). Both patients
presented with hyperinsulinism, macrosomia, macroglossia, omphalocele, organomegaly, and
lateralized overgrowth. Genome-wide single nucleotide polymorphism (SNP) microarray analysis
was carried out using the Illumina CRC BeadChip as previously described (Conlin et al., 2010).

5.2. iPSC generation, culture and maintenance
Fibroblast derivation and culture
Skin samples were collected during surgical procedures and fibroblasts were dissociated
using collagenase Type 2 (Worthington) in RPMI 1640 (1.6 g in 200 ml) for 30 minutes. In
preparation for reprogramming, Patients 1 and 2 fibroblasts and normal human fetal male
fibroblasts IMR-91 (Coriell Institute for Medical Research) were cultured in fibroblast media
(RPMI with 20% fetal bovine serum (Hyclone SH30070.03), 1X penicillin/streptomycin, 1X
GlutaMAX)) and fed every 2 days.
Viral Reprogramming
Patient 1 fibroblasts were reprogrammed using the inducible stem cell cassette
(STEMCCA) and reverse tetracycline-controlled transactivator (rtTA) virus (Sommer et al.,
2009) as previously described (Anguera et al., 2012; Woo et al., 2016). 5x104 Patient 1
fibroblasts were seeded onto one well of a 6-well plate. The following day, in fibroblast media,
cells were infected with STEMCCA (100 μl) and rtTA (80 μl) viruses prepared by Woo et al.
(Woo et al., 2016). Two days after infection, the media was replaced with fresh fibroblast media.
The following day, cells were passaged onto three 10 cm gelatinized (0.1% gelatin) plates in
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fibroblast media with 2μg/ml doxycycline (Sigma 9891) and transferred to a low oxygen
(5%CO2, 4%O2) incubator. A portion of infected cells was also plated onto 12-well plates -/+ 2
μg/ml doxycycline (Sigma 9891) to test for efficiency of infection by measuring OCT4 induction
by immunohistochemistry. For subsequent days of reprogramming, cells were fed daily with
WIBR hES media (DMEM-F12 with 15% fetal bovine serum, 5% KnockoutTM Serum
Replacement, 0.1875% Sodium Bicarbonate, 1X nonessential amino acids, 1X
penicillin/streptomycin, 1X GlutaMAX, 0.1mM 2-mercaptoethanol, 10ng/ml β-FGF (R&D
Systems)) and freshly added 2 μg/ml doxycycline, as described (Woo et al., 2016).
Episomal reprogramming
Patient 2 fibroblasts and IMR91 fibroblasts (Coriell Institute for Medical Research Cell
Repository) were reprogrammed using episomal plasmids, as previously described (Okita et al.,
2011; Bershteyn et al., 2014). To reprogram patient 2 and IMR-91 fibroblasts, we electroporated
600,000 cells with plasmids (1μg of each) CXLE-hOCT3/4-shp53, pCXLE-sSK, pCXLE-HUL,
and pCXLE-EGFP plasmid (Okita et al., 2011) (Addgene) using the Neon® Transfection System
100-ml-kit according to manufacturer’s instruction. Conditions for electroporation were 1650 V,
10ms, and three pulses (Bershteyn et al., 2014). As previously described (Okita et al., 2011),
pCXLE-EGFP was used to monitor the efficiency of electroporation and gradual loss of
plasmid/eGFP expression with prolonged culture. Cells were recovered in fibroblast media and
plated onto 10 cm and 6 cm gelatinized plates and incubated in a standard high oxygen incubator.
The following day, media was changed to the WIBR hES media, and plates were moved to a low
oxygen incubator and fed daily for 6 days. During initial 7 days of reprogramming of the patient
fibroblast patient 2 and IMR91 fibroblasts, the WIBR hES media was supplemented with 37.5
μg/ml Vitamin C (VC) (Sigma 49752), based on pervious analysis (Chung et al., 2010) and
considering the amount of VC already in the KnockoutTM Serum Replacement (Stadtfeld, Park
and Hochedlinger, 2012). On the 7th day after electroporation, fibroblasts were expanded onto
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multiple 6 cm and 10 cm gelatinized plates and fed daily with WIBR hES media, analogous to
our viral reprogramming method (Woo et al., 2016).
Picking and culturing iPSCs
Colonies were picked between day 18 and 28 of reprogramming into media with 50%
WIBR hES media and 50% serum free iPSC media (DMEM-F12 with 20% KnockoutTM Serum
Replacement, 1X nonessential amino acids, 1X penicillin/streptomycin, 1X GlutaMAX, 0.1mM
b-mercaptoethanol, 10ng/ml β-FGF (R&D Systems)). Colonies were picked and passaged onto
gelatin coated 6-well plates that were plated with 125,000 Mitomycin C treated CF1 mouse
embryonic fibroblasts (MEFs)/well. Clones were weeded and fed every 1-2 days with serum free
iPSC media. iPSCs were manually passaged every 5-7 days. On the days of picking, passaging
wells with <5 colonies, and thawing iPSCs, 0.5mM ROCK inhibitor (StemMACSTMThiazovivin)
was routinely added to media; ROCK inhibitor was removed the following day by changing to
fresh media.
Maintenance of iPSC lines
Adapted from Mills et al., 2014, the iPSC lines were cultured on irradiated mouse
embryonic fibroblast (MEF) feeder cells in DMEM-F12 medium supplemented with 2 mM
glutamine, 20% Knockout Serum Replacement (InVitrogen), 1X NEAA, 1X
penicillin/streptomycin, 0.1 mM b-mercaptoethanol, and 5-10 ng/ml b-FGF (R&D Systems).
Cells were cultured at 37°C in an environment of 5% CO2, 5% O2, 90% N2. When the cells
reached approximately 80% confluence, they were passaged using TrypLE (InVitrogen). All
iPSC lines had normal karyotypes and were mycoplasma negative. The CHOPWT14 line derived
as previously described as also used as a control line (Thom et al., 2020).
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5.3. Characterization of iPSCs
Immunofluorescence staining
Cells were fixed in 4% paraformaldehyde (Electron Microscopy Sciences) for 20min at
room temperature, permeabilized in 0.1% Triton-X100 (EMD), blocked with 3% bovine serum
albumin (Calbiochem), and incubated overnight at 4°C in following primary antibodies: SSEA1
(1:100, Millipore), SSEA3 (1:100, Millipore), SSEA4 (1:100, Millipore), TRA1-60 (1:100,
Millipore), TRA1-81 (1:100, Millipore) and Oct4 (1:250, Novus biologicals). Cells were then
incubated with appropriate secondary antibodies: Alexa Fluor 488 goat anti-mouse IgG (1:1000,
Life Technologies), Alexa Fluor goat anti-mouse IgM (1:1000, Life Technologies) and FITC-goat
α-rabbit IgG (1:1000, Novus biologicals) for 30min at room temperature.
Karyotyping
Cells were treated with 0.2ug/ml Colcemid (Sigma) for 4 hours at 37°C, collected using
0.25% Trypsin and lysed in 0.56% (w/v) KCl for 25min at room temperature. Cells were fixed in
methanol:acetic acid (3:1) solution, spread to slides, stained with Giemsa (Sigma).

5.4. Embryoid Body generation
iPSCs were dislodged from MEF feeder cells using pipette tips or cell scrapers and
transferred to low attachment plates (Corning) in 50% WIBR hES media and 50% EB
differentiation media (DMEM-F12 with 20% fetal bovine serum, 1X nonessential amino acids,
1X penicillin/streptomycin, 1X GlutaMAX, 0.1mM b-mercaptoethanol). ROCK inhibitor was
added for the first day of EB differentiation at final concentration of 0.5mM and removed the
next day by changing to fresh EB differentiation media. After 7 days, EBs were transferred to
gelatin-coated plates and cultured for 7 days. Media was changed every other day. EBs were
collected on day 14.
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5.5. Endoderm induction and hepatic differentiation of iPSC lines
The induction of definitive endoderm followed by hepatic specification and maturation of
all iPSC lines was performed as previously described (Holtzinger et al., 2015) adapted from
Ogawa et al., 2013, 2015. Briefly, cells were cultured in an environment of 5% CO2, 5% O2,
90% N2 as a monolayer on Matrigel-coated dishes followed by endoderm induction using 100
ng/ml activin A (R&D Systems) and 2 μM CHIR 99021 (Tocris) in RPMI supplemented with 2
mM glutamine, 0.5 mM ascorbic acid (Wako Chemicals) and 4.5x10-4 M MTG (Sigma). After 24
hours, cells were cultured in the same medium mixture supplemented with 5 ng/ml β-FGF (R&D
Systems) and 0.5 mM ascorbic acid. This induction phase was continued to day 7 by adding every
other day 100 ng/ml activin A and 5 ng/ml β-FGF in serum-free differentiation medium (SFD)
(Gadue et al., 2006) supplemented with glutamine, ascorbic acid, and MTG. Hepatic specification
was induced by culturing the cells in 40 ng/ml β-FGF and 50 ng/ml BMP4 (R&D Systems) in a
medium mixture of 75% DMEM (1g/L glucose) (Gibco), 25% Ham-F12 (Corning), B27 with
retinoic acid and 10% BSA supplemented with glutamine, ascorbic acid, and MTG every other
day between days 7-13. Hepatic maturation was induced by adding 20 ng/ml HGF (R&D
Systems), 40 ng/ml dexamethasone (Sigma), and 20 ng/ml oncostatin M (R&D Systems) in the
same medium every other day between days 13-21. This maturation phase was continued until
day 24 by culturing the cells at normoxic conditions in the same cytokine and medium mixtures
except for DMEM (4.5g/L glucose) (Gibco).

5.6. Flow Cytometry and Cell Sorting
Adapted from Mills et al., 2014, briefly single cell suspensions were prepared by treating
the cells with 0.25% Trypsin/EDTA for 5-10 minutes. For extracellular staining, cells were
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incubated with antibodies diluted in Dulbecco’s phosphate-buffered saline (DPBS) (Corning)
containing 0.5% BSA (Sigma) and 0.05% Sodium Azide (Sigma) for 15-30 minutes at room
temperature. Only iPSC lines expressing >90% stemness markers, SSEA3/4 and Tra-1-60/81,
were used for differentiation. For intracellular staining, cells were fixed with 1.6%
paraformaldehyde (Electron Microscopy Science) for 30 minutes at 37°C, washed, and
permeabilized using 1X saponin buffer (Biolegend). Cells were incubated with primary
antibodies diluted in saponin buffer for 30 minutes at room temperature, washed, and incubated
with the appropriate secondary antibody. Following endoderm induction, only iPSC lines coexpressing >90% CXCR4 and c-kit definitive endoderm markers at day 7 were continued for
hepatic specification and maturation. Samples were analyzed using a Cytoflex flow cytometer
(Becton Dickinson) and data analysis was performed using the FlowJo (Treestar) software
program. Cell sorting was performed using a FACSAria II (BD Biosciences) cell sorter. During
differentiation, cell surface expression of the hepatocyte marker, ASGR1 (Peters et al.
Development 143:1475, 2016), was analyzed on cells at day 20 of differentiation. If expressed,
ASGR1+ cells were sorted at day 24 and collected in 15 ml tubes with 2 ml DPBS. Cells were
evenly distributed into 3 tubes, pelleted and stored at -80°C. All antibodies are described in Table
5.1.

5.7. Isolation of MEFs
MEFs were isolated from E12.5 C57/BL6 strain wild-type embryos as previously
described (Verona et al., 2008).

5.8. Gene Expression Analysis
Sample collection and RNA isolation
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For collection, iPSC lines were manually dislodged using pipette tips or cell scrapers and
embryoid bodies (EBs) were dissociated using 0.25% Trypsin-EDTA. Mouse tissue samples were
flash-frozen in liquid nitrogen immediately after collection and stored at -80°C until processed.
Tissues were ground using pestles, syringes and needles in either TRIzol (Thermo Fisher
scientific) or RLP buffer included in RNeasy Mini kit (Qiagen). RNA was isolated according to
the manufacturer’s instructions.
cDNA synthesis and gene expression analysis
To remove genomic DNA contamination, RNA samples were treated with DNase
(Promega) or processed through on-column DNase I treatment (Qiagen). cDNA was synthesized
using Superscript III reverse transcriptase (Invitrogen) and random primers (Roche). Product
from cDNA synthesis without RT enzyme was used as a negative control to confirm the absence
of genomic DNA. For qRT-PCR assay, Power SYBR Green mater mix (Applied Biosystems) and
primers in final concentration of 0.2μM were used on an ABI 7300 machine. Each sample was
run in triplicate, and the mean value of triplicate is plotted in graphs. 5ng of cDNA was used per
reaction. For each primer set, reaction efficiency (E) was calculated using standard curve, and E-Ct
value of each gene was normalized to geometric mean of E-Ct values of housekeeping genes. For
human fibroblasts, iPSCs and EB samples, GAPDH and PPIG were used as housekeeping genes.
For mouse tissue samples, Nono, Arbp and Rpl13a were used for normalization. Primers are listed
in Table 5.2.
Allele-specific expression
10ng of cDNA was used for RT-PCR. PCR products were digested with restriction
enzyme MluCI (NEB, R0538S) for 3hrs at 37°C, and then run on 12% polyacrylamide gels. PCR
product digests using pure B6 and CAST strain cDNA were run together as controls for complete
digestion. Images were analyzed using FIJI (v2.0.0, Schindelin et al., 2012) to quantify the band
densitometry. Primers and PCR conditions are listed in Table 5.2.
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5.9. Genotyping
Fibroblasts and iPSC clones
Microsatellite marker AFM217YB10 was used to genotype parental alleles of patient 1
and 2 gDNA. Single Nucleotide Polymorphisms (SNP) rs10840159 (A/G) in patient 2 were used
for genotyping iPSC clones, facilitated by restriction enzyme digest of polymorphisms. See Table
5.3 for details.
Mouse lines
Genomic DNA for PCR genotyping was isolated from each animal as previously
described (SanMiguel, Abramowitz and Bartolomei, 2018). Primers used for sex genotyping and
genotyping of hIC1, △H19 and △3.8 alleles are listed in Table 5.2. For all genotypes, the
maternal allele is listed first and the paternal allele second.

5.10. DNA Methylation Analysis
Isolation of genomic DNA
Samples were first digested in lysis buffer (50mM Tris, pH8.0, 100mM EDTA, 0.5%
SDS) with proteinase K (Sigma-Aldrich) overnight at 55°C. Genomic DNA was isolated using
Phenol:Chloroform:Isoamyl Alcohol (Sigma-Aldrich P3803) and ethanol precipitation. DNA
samples resuspended in water were stored at -20°C, and samples resuspended in TE buffer were
stored at 4°C for further analysis.
Bisulfite treatment and DNA methylation analysis
500-1000ng of gDNA was subjected to bisulfite mutagenesis using the Epitect kit
(Qiagen) according to the manufacturer’s protocol. 25ng bisulfite-mutagenized DNA was used
per PCR for COBRA, pyrosequencing, cloning and sequencing. For COBRA, bisulfite-treated
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DNA was PCR amplified as described previously (Hur et al., 2016), except that total of 41 PCR
cycles was used; PCR products were digested with appropriate restriction enzymes for 3 hours at
37°C; enzymes were then inactivated for 10 min at 65°C; bands were resolved using 12%
polyacrylamide gel and were quantified using ImageJ. Pyrosequencing was performed as
described previously (Hur et al., 2016) using Qiagen assay ADS003 (catalog no. PMC0007406).
Cloning and sequencing of bisulfite-treated DNA was performed as described in Hur et al., 2016,
except that a total of 41 PCR cycles were used; a minimum of two rounds of PCR was performed
per analysis. Primers, PCR annealing temperatures, and restriction enzymes used are listed in
Table 5.4.

5.11. RNA Sequencing library preparation and analysis
Standard RNA-Seq was performed by GeneWiz from frozen cell pellets. RNA was
isolated using the Rneasy Plus mini kit (Qiagen). PolyA selection was performed to enrich for
mRNA transcripts. RNA eluate concentration was assessed by Qubit (Thermo Fisher) and quality
was assessed by TapeStation (Agilent). Sequencing was performed on the Illumina HiSeq 2x150
bp. Read counts throughout processing are described in Table S9. Quality of raw fastq reads was
assessed using FastQC (Andrews et al., 2015). Adaptor trimming for Illumina paired-end libraries
was applied using Cutadapt (Martin, 2011). Reads were aligned to the hg19/GRCh37 reference
using STAR (Dobin et al., 2013). Count matrices were generated using HTSeq-Count (Anders,
Pyl and Huber, 2015) and read into DESeq2 (Love, Huber and Anders, 2014) to perform the
variance stabilizing transformation and statistical analysis. Venn diagram plot was generated
using the VennDiagram R package (Chen and Boutros, 2011). Transformed read counts were
used to make expression boxplots, heat maps were generated using Heatmaply R package (Galili
et al., 2018), and for GSEA (Mootha et al., 2003; Subramanian et al., 2005). Gene sets with
GSEA enrichment were: CHIANG_LIVER_CANCER_SUBCLASS_PROLIFERATION_UP,
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CHIANG_LIVER_CANCER_SUBCLASS_PROLIFERATION_DN,
CAIRO_HEPATOBLASTOMA_UP, CAIRO_HEPATOBLASTOMA_DN,
GO_CELLULAR_RESPONSE_TO_INSULIN_STIMULUS,
PACHER_TARGETS_OF_IGF1_AND_IGF2_UP,
CELL_PROLIFERATION_GO_0008283, and
HALLMARK_PI3K_AKT_MTOR_SIGNALING. STRING was used to generate the proteinprotein interaction network of top differentially expressed genes (Szklarczyk et al., 2019).

5.12. Animal studies
All studies in this dissertation complied procedures approved by the Institutional Animal
Care and Use Committee (IACUC) at the University of Pennsylvania. hIC1 (Hur et al., 2016) and

△3.8 (Thorvaldsen et al., 2002, 2006) mouse models were previously described. Timed breeding
was performed as previously described (SanMiguel, Abramowitz and Bartolomei, 2018). Vaginal
sperm plugs were checked to calculate the embryonic days, and the day of the plug was marked
as E0.5. Visual staging confirmed the embryonic days at the time of dissection. All mice were
maintained on C57/BL6 background for more than 10 generations if not noted otherwise.

5.13. Generation of △H19 allele
This section was borrowed from Dr. Stella K. Hur’s thesis.
gRNA design
gRNA sequences were designed using the program (http://www.genomeengineering.org/crispr/?page) and are shown below. PAM sequences are underlined. 3A and 3B
target 3’end, and 5A and 5B target 5’end of the H19 gene.
Pair A

Pair B
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3A CTTCAATATAATGCGACTCA

3B CAATATAATGCGACTCATGG

TGG

GGG

5A AACGTGCGCTGGAACGATAC

5B ATCAGTACATGGCCCCGCCG

AGG

GGG

gRNA generation and injection
All procedures were done per guidance of Dr. Catherine May in the laboratory of Dr.
Klaus Kaestner. The protocol provided by Dr. Catherine May was modified from Yang et al.
(Yang, Wang and Jaenisch, 2014). For sgRNA preparation, px335 plasmid (Addgene #42335)
was PCR amplified using the primer sets:
Forward: 5’TTAATACGACTCACTATAGGNNNNNNNNNNNNNNNNNNNNgttttagagctagaaatagc- 3’

Reverse: 5’-AGCACCGACTCGGTGCCACT-3’
The underlined 20 nucleotides of the forward primer were substituted with each gRNA sequence
excluding the PAM sequence. Reverse primer is universal for all PCR reactions. PCR reaction
was setup using the Phusion high-fidelity DNA polymerase (NEB, cat. No. M0530). To get
enough materials for in vitro transcription, 2-3 PCR reactions were set up per gRNA.
Component

Amount (µl/reaction)

5X Phusion HF Buffer

20

10mM dNTPs

2

10µM Primer Mix

5

DNA polymerase

1

Template DNA (pX335), 10ng

2

H2O

70
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Total Volume

100

Cycle number

Denature

1

98°C, 30s

2-34

98°C, 30s

Anneal & Extend

Final Extend

72°C, 20s

35

72°C, 1 min

Hold at 4°C

PCR products were ran on a 2% agarose gel. Once ~117bp products are verified, PCR products
are gel-purified using the Qiagen Gel Extraction kit according to the manufacturer’s instruction.
One column was used to pool the same PCR product and DNA was eluted in 15μl RNAse free
water. In vitro transcription of gRNA was setup using the gel-purified product as templates. T7
High Yield RNA Synthesis kit (NEB, E2040S) was used according to the kit protocol. More than
2 tubes of reactions per gRNA were setup to increase the yield.
Component

Amount (µl/reaction)

10X Reaction Buffer

1.5

ATP

1.5

GTP

1.5

UTP

1.5

CTP

1.5

Template DNA (500 ng)

X

T7 RNA polymerase Mix

1.5

Nuclease-free H2O

X

Total Volume

20
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Reactions were incubated at 37°C overnight. Transcribed gRNA was purified using the
MEGAclear kit (Life Technologies) according to the kit protocol. To prevent the injection
needles from being clogged during microinjection, the eluted gRNA was spun twice at top speed
at 4°C for 20min, with each spin followed by transfer of suspension to a new tube. The eluted
gRNA was concentrated according to the protocol so that the final concentration is around 1-2
μg/μl. RNA quality and quantity were checked using a bioanalyzer. Injection mix was prepared as
follow:
Component

Stock Concentration

Stock Volume (µl)

Final Concentration

sgRNA (Left)

500 ng/µl

3

50 ng/µl

sgRNA (Right)

500 ng/µl

3

50 ng/µl

Cas9 mRNA

1 µg/µl

3

100 ng/µl

Injection buffer*

21

Total

30
*Injection buffer: 10 mM Tris / 0.1 mM EDTA, pH 7.5 prepared with sterile water.
The injection mix was spun at top speed at 4°C for 20min, and the suspension was

transferred to a new tube for injection. Either pair A or pair B was injected per zygote stage
embryo by the Transgenic and Chimeric Mouse Facility at the University of Pennsylvania.
Mouse breeding and genotyping
The targeted allele was validated using Southern blot as previously described
(Thorvaldsen, Duran and Bartolomei, 1998). Obtained chimeras and germ line transmission
animals were PCR-genotyped for the △H19 allele using primers (Tables 5.2).

5.14. Histological analysis
Sample collection, processing and immunohistochemistry
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Mouse tissue samples were collected in cold PBS, fixed overnight in 4%
paraformaldehyde or 10% phosphate-buffered formalin and processed through ethanol
dehydration. Tissues were paraffin-embedded and sectioned for further staining analysis.
Hematoxylin and eosin staining was performed using a standard protocol. Placental CD34
staining was performed as previously described (Vrooman et al., 2020).
Ventricular wall thickness
The thickness of ventricular wall was measured on hematoxylin-eosin stained heart
sections using Adobe Photoshop. Minimum 3 distinct sections were quantified for each mouse in
each genotype. Measurements were taken in a blinded manner by Kashviya Suri.
Placenta histological analyses
Jz/Lb ratio was measured using FIJI (ImageJ v2.0.0, Schindelin et al., 2012) in a blinded
manner. CD34 stained placental sections were digitally scanned at 20x using Aperio VERSA 200
platform in Comparative Pathology Core (CPC) at School of Veterinary Medicine at the
University of Pennsylvania. Images were analyzed via Aperio Microvessel Analysis algorithm as
previously described (Vrooman et al., 2020).

5.15. Statistical Analysis
Differences between two groups were evaluated using Student’s t-test. For three or more
groups, ordinary one-way analysis of variance (ANOVA), followed up with Tukey’s multiple
comparisons test, was used. Two-sided Fisher’s exact test was used to compare the occurrence of
the thrombi in the wild-type and +/hIC1 placentas. All analyses were performed using GraphPad
Prism software. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, n.s. = not significant.
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Table 5.1 Antibodies and markers for hepatocyte differentiation
Cell Surface Markers
Antibody

Company

Catalogue #

Dilution

SSEA3

Biolegend

330306

1:50

SSEA4

Biolegend

330408

1:50

Tra-1-60

Biolegend

330614

1:50

Tra-1-81

Biolegend

330706

1:50

ASGR1

BD Pharmingen

563655

1:20

Intracellular Markers
Antibody

Company

Catalogue #

Dilution

CXCR4

BD Pharmingen

555976

1:100

c-kit

BD Biosciences

340529

1:100

AFP

R&D Systems

MAB1368

1:400

AAT

Santa Cruz Biotechnology

Sc-59438

1:400

Mouse IgG1 Isotype

Abcam

ab81032

1:200

Goat anti-mouse IgG1

Jackson Immunoresearch

115-545-205

1:400
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Table 5.2. Primers and PCR conditions utilized in this study.
Primer

Forward

Reverse

Reference

Human qRT-PCR primers
(Teo et al.,
AFP

AGCTTGGTGGTGGATGAAAC

CCCTCTTCAGCAAAGCAGAC

2011)
(Park et al.,
GATA4

TCCCTCTTCCCTCCTCAAAT

TCAGCGTGTAAAGGCATCTG

2008)
(Chang et
HAND1

TGCCTGAGAAAGAGAACCAG

ATGGCAGGATGAACAAACAC

al., 2020)
(Cai et al.,
RUNX2

CACTCACTACCACACCTACC

GTCGCCAAACAGATTCATCC

2006)
NCAM1

FGF5

ATGGAAACTCTATTAAAGTGAA

TAGACCTCATACTCAGCATTCC

(Park et al.,

CCTG

AGT

2008)

CAAAACACTTAACATATTGGCT

(Higgins et

TCG

al., 2014)

CGCTATGTCTTCCTCTTCTGC

H19

GCAAGAAGCGGGTCTGTTT

GCTGGGTAGCACCATTTCTT

(Hiura et

IGF2

ACACCCTCCAGTTCGTCTGT

GAAACAGCACTCCTCAACGA

al., 2013)

GAPDH

GTCGTGGAGTCCACTGGCGTC

TCATGAGTCCTTCCACGATAC

GAAGAGTGCGATCAAGAACCCA

GTCTCTCCTCCTTCTCCTCCTAT

(Cheng et

TGAC

CTTT

al., 2012)

OCT4

CGACCATCTGCCGCTTTG

GCCGCAGCTTACACATGTTCT

(Anokye-

SOX2

ACAGCAAATGACAGCTGCAAA

TCGGCATCGCGGTTTTT

Danso et

NANOG

CCAAAGGCAAACAACCCACTT

CGGGACCTTGTCTTCCTTTTT

al., 2011)

PPIG

Mouse qRT-PCR primers
Arbp

(Hur et al.,

TCCCACTTACTGAAAAGGTCAA
TCCGACTCTTCCTTTGCTTC
G

2016)
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Nono

GCTCGTGAGAAGCTGGAGAT

TTCTTGACGTCTCATCAAATCC

(Plasschaert
and

Rpl13a

Bartolomei,
ATCCCTCCACCCTATGACAA

GCCCCAGGTAAGCAAACTT

2014)

(Hur et al.,
H19

GTCTCGAAGAGCTCGGACTG

ACTGGCAGGCACATCCAC

2016)
(Weaver,
Susiarjo
Igf2

CGCTTCAGTTTGTCTGTTCG

GCAGCACTCTTCCACGATG

and
Bartolomei,
2009)

Mouse allele-specific expression primers
H19*

TGATGGAGAGGACAGAAGGG

TTGATTCAGAACGAGACGGAC

(de Waal et

Igf2**

ATCTGTGACCTCTTGAGCAGG

GGGTTGTTTAGAGCCAATCAA

al., 2015)

*

PCR condition: 95°C 2min, (95°C 15s, , 60°C 10s, 72°C 20s)x26-30 cycles, 72°C 5min

**

PCR condition: 95°C 2min, (95°C 15s, , 58°C 10s, 72°C 20s)x26-30 cycles, 72°C

5min
Mouse genotyping primers#
(Hur et al.,
hIC1

CCTTCACGGCTTTGACACTC

GTCAACCGGAGGCACAGTAT

2016)

△H19

TTGTGGTGAGGCTGTCTTTG

CCTATTCCCCATTCCATCCT

This study
(Thorvaldse

△3.8

CCAACTGAGAGGGCCATAGTGT
CCACAGAGTCAGCATCCAC

n et al.,

GAG

2002)
#

PCR condition: 95°C 2min, (95°C 15s, , 58°C 10s, 72°C 20s)x35 cycles, 72°C 2min
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Table 5.3. Primer sequences and PCR conditions for genotyping pUPD11 iPSC lines.
Patient

Forward

Reverse

cell linesa
Patient 1

GGGGCATCTGTGGCT

TCCGGTTTGGTTCAGG

A

Patient 2

a

Restriction

Polymorphism

Enzyme

Assayed

Not

AFM217YB10

applicable

AACACCTTAGGCTGG

TCGGAGCTTCCAGACTA

TGG

G

MscIb

rs10840159

PCR conditions to assay Patient 1 microsatellite repeat marker: 94°C 2min, (94°C 30s, 57°C

30s, 72°C 30s)x35 cycles, 72°C 5min. To assay Patients 2 SNPs, PCR conditions are: 94°C 4min,
(94°C 90s, 60°C 60s, 72°C 90s)x31 cycles.
b

The common (maternal) allele of Patient 2 gDNA is digested with MscI at rs10840159 (A/G).

Table 5.4. DNA methylation analysis primers and conditons.
COBRA
Restriction
Primer

Forward

Reverse

Reference
enzyme

IC1*

IC2*
*

GGGAGATGAGATATTTTGG

CCCCATCCAAAAAA

HPYCH4I

(Hur et

TGATAATG

AACTTAAAC

V

al., 2016)

GGTAGGATTTTGTTGAGGA

CACACCCAACCAAT

GTTTT

ACCTCATA

(Chang et
RsaI
al., 2020)

PCR conditions: 95°C 15min, (95°C 30s, 60°C 30s, 72°C 30s)x41 cycles, 72°C 5min.

Bisulfite sequencing
hIC1 CTS3

GGGAGATGAGATATTTTGG

CCCCATCCAAAAAA

Not

(Beygo et

TGATAATG

AACTTAAAC

applicable

al., 2013)

105

PCR conditions: 95°C 15min, (95°C 30s, 60°C 30s, 72°C 30s)x41 cycles, 72°C 5min.

Pyrosequencing for hIC1
hH19pyroseq2F
hH19pyroseq2Rbiotinylated

Qiagen, Assay name ADS003 Catalog No PMC0007406

(Hur et
al., 2016)

hH19pyroseq2
seq
PCR conditions: 95°C 15min, (95°C 30s, 55°C 30s, 72°C 30s)x45 cycles, 72°C 5min.
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